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Abstract
In the past decade there have been great advances and emergence of new techniques
in the field of gene expression profiling. As the popularity of these techniques grew,
the amount of data that gets generated has also grown. The task of analyzing this
data to create a global picture to identify the biological pathways that are relevant
to the study has been addressed by many. These approaches (collectively termed as
enrichment analysis) have also grown in sophistication and accuracy making them
the default step following a gene profiling experiment. However, enrichment analysis
approaches do not provide pointers to likely regulators in their results.
In this project we built a system called Regulation Expression Pathway Analysis
or REPA to facilitate the biological interpretation of results from high throughput
gene expression profiling experiments. In particular, we provide researchers with gene
sets that were most active in the biological phenomenon under study and their likely
regulators. Users can input the gene expression profile data from their expression
profiling experiments in REPA and get a list of disturbed gene sets and inferred
transcription factors that possibly regulate these gene sets.
To build this system first we processed the transcription factor binding data from
the ENCODE project to quantify the strength of regulation that each transcription
factor has on each gene set. Then we build a gene expression enrichment analysis
system that can analyze the gene expression profiling data and list the most active
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gene sets. Finally we combine the results from the previous two steps to arrive at a
more complete picture that gives users information about not only the most active
gene sets, but also about the most likely regulators of these gene sets.
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Chapter 1
Introduction
It is now common knowledge that the entire genetic information of an organism is
coded in its DNA. Therefore the knowledge of the exact sequence of the DNA of an
organism is a valuable resource in the quest to understand how that organism func-
tions. In recent times great advances were made in the development of techniques
that enable high speed DNA sequencing. Any method or technology that can deter-
mine the exact order of the four bases of DNA is called a DNA sequencing technique.
Another method that have grown in popularity is the expression profiling techniques
which allow researchers to check the activity levels of thousands of genes at once.
These gene expression profiling techniques are extremely useful in determining the
functions of genes. The data generated from such methods is huge, but without
proper interpretation, is not of much use.
Our project is in the field of bioinformatics, which is an interdisciplinary field
dealing with the development and use of computer software and databases to facilitate
and enhance biological research. The main objective of this project is to facilitate the
biological interpretation of the results from gene expression profiling experiments. In
particular, we provide researchers with gene sets (or biological pathways) associated
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to the biological phenomenon under study and their likely regulators. Gene sets are
set of genes which have some feature in common such as genes that are involved in a
pathway. To achieve this goal we built a software system called Regulation Expression
Pathway Analysis (REPA) where users can input the gene expression profile data from
their expression profiling experiments and get a list of disturbed gene sets and inferred
transcription factors that possibly regulate these gene sets.
REPA uses an enrichment analysis approach called Functional Class Scoring or
FCS. Enrichment analysis are a set of software tools and techniques which attempt
to interpret the data from gene expression profiling experiments by finding functions
and pathways that summarize the observations. Over the past decade as expression
profiling grew in popularity, the need for accurate enrichment analysis also grew.
Many algorithms and software tools were developed to address this. An in depth
review can be found in the paper (Khatri, Sirota, and Butte 2012).
In REPA, we have mainly two modules. The first module links the transcription
factors to individual gene sets. The second module performs enrichment analysis on
the gene expression data. Combining the results from these two modules allows REPA
to predict three things:
• Transcription factors that may regulate a given pathway. This is the result from
the first module.
• Pathways that are affected in the given experiment. This is the result from the
second module.
• Transcription factors that are most likely regulating the pathways that are most
affected in the study. This is the result of combining the output of the two
modules.
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Over a hundred systems were developed in the past decade for performing en-
richment analysis in gene expression data. Some of the most widely used tools are
Gene Set Enrichment Analysis or GSEA (Subramanian et al. 2005), and Parametric
Analysis of Gene set Enrichment or PAGE (Kim and Volsky 2005). In 2009 a new
method called GAGE, or Generally Applicable Gene-set Enrichmen (Luo et al. 2009),
was published which could handle datasets of different sample sizes or experimen-
tal designs. GAGE showed significantly improved results compared to GSEA and
PAGE (Luo et al. 2009). For validation, we compared the second module of REPA to
GAGE. The novel aspect of REPA is that we are using hypothesis based statistical
testing to find regulators that control entire gene sets. Then we combine the results
from the enrichment analysis module to present more detailed analysis of the data
obtained from gene profiling experiments. Previous tools only perform enrichment
analysis on the gene expression data and provide gene sets that are perturbed in the
experiment whereas REPA also provides information about the likely regulators of
the perturbed pathways.
This thesis is organized in 5 chapters. After this initial introductory chapter, we
discuss the necessary biology that is required to understand this project in chapter
2. We also look at the work that has been done so far in this area, describe the
problem statement, and existing solutions. In chapter 3 we take a detailed look at
REPA and all its components. System validation and comparison is presented in
chapter 4 followed by a conclusion in chapter 5. The work described in this thesis
has been accepted for publication in the IEEE/ACM Transactions on Computational
Biology and Bioinformatics journal and presented at the Great Lakes Bioinformatics
Conference 2015.
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Chapter 2
Background Knowledge and
Related Work
This chapter describes the biological concepts required to understand the work done.
2.1 Flow of information in biological systems
The process of transmission of the genetic information from the genome of an organism
to its phenotype (i.e. the expression of observable characteristics as an individual) is
a complex process. A simplified description is provided here, as it is necessary to the
understanding of this project.
Figure 2.1 shows how genetic information flows within a biological system. This
was first proposed by Frank Crick in 1958 and published later in 1970 (Crick et al.
1970). Generally this information flows from DNA to DNA (replication), DNA to
RNA (transcription) and RNA to proteins (translation).
To fully understand the diagram we need to learn more about the macromolecules
such as DNA, RNA, and proteins, along with processes such as replication, translation,
12
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Figure 2.1: Flow of information in biological systems (Horspool 2008)
and transcription. This section describes each of them one by one.
2.1.1 Deoxyribonucleic acid (DNA)
The substance that is responsible for carrying the genetic information from parents
to offspring in most living organisms, including all prokaryotic and eukaryotic cells
and in many viruses, is an organic chemical of a complex molecular structure called
Deoxyribonucleic acid, or DNA (Klug et al. 2012).
Figure 2.2: Location of DNA in a cell (Mariana Ruiz 2012)
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As shown in figure 2.2, DNA resides in the nucleus of eukaryotic cells, where
inside the chromosomes, the DNA is condensed in a DNA - protein complex called
chromatin. When the chromatin is uncoiled, its main component is revealed: the
DNA molecule.
Figure 2.3: The structure of the DNA double helix (Zephyris 2011)
DNA has a double helix structure (Watson, Crick, et al. 1953), that looks like a
long spiraling ladder (figure 2.3). It is formed of millions of elemental molecules, called
nitrogenous bases, linked together in chains. The sequence in which the nitrogenous
bases are linked amounts to a code that determines the characteristics of an individual,
such as their eye color. These coded instructions are called genes. Genetic information
is different for every individual making each of us unique.
14
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The genetic material, or the DNA, of an organism contains instructions to control
all everyday cellular activities (Hunter 2012). Bases, or nucleotides, are the building
blocks of DNA, and there are four types: Adenine, Guanine, Cytosine and Thymine.
The structure of these bases are given in the figure 2.3.
The configuration of the DNA molecule is highly stable, allowing it to act as a
template for the replication of new DNA molecules, as well as for the production
(transcription) of the related RNA (ribonucleic acid) molecule.
2.1.2 Ribonucleic acid (RNA)
RNA is also a nucleic acid like DNA but unlike DNA it is a single stranded molecule.
Another difference between the two is that instead of thymine the fourth base pair in
RNA is uracil. The structural differences between the two nucleic acids are shown in
figure 2.4.
Figure 2.4: Comparison of a single-stranded RNA and a double-stranded DNA (Sponk
2011)
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There are different types of RNA molecules, but in this thesis we are only interested
in the RNA molecule whose main function is to carry the genetic information from
the DNA to proteins via the steps of transcription and translation. This type of RNA
molecule is called messenger RNA or mRNA (Hunter 2012).
mRNA carries the coding instructions for protein synthesis from DNA to the
ribosome. During translation, the mRNA molecule specifies the sequence of the
amino acids in a polypeptide chain and thereby provides a template for joining amino
acids. (Pierce 2005). The folding of these amino acid chains gives birth to a protein
molecule.
2.1.3 Proteins
Figure 2.5: Myoglobin protein 3D structure (AzaToth 2008)
Proteins are large macromolecules that perform a wide array of functions. Each
organism uses thousands of different proteins in their life span (Hunter 2012). Some
functions that proteins perform are the catalyzation of metabolic reactions, the repli-
cation of DNA, responses to stimuli, and the transportation of molecules from one
16
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location to another, among many more.
For example, the protein myoglobin is an iron and oxygen binding protein. It is
commonly found in the muscle tissues of vertebrates. It’s 3D structure is shown in
figure 2.5 (Kendrew et al. 1958).
2.1.4 Gene
A gene is a unit of heredity in a living organism. A gene is usually responsible for
influencing certain characteristics of the organism. It is normally a stretch of DNA
that codes for a type of protein, or for an RNA molecule that has a function. Genes
only have an effect on the cell when they are expressed (transcribed).
2.1.5 Gene expression
Figure 2.6: Steps in gene expression (Forluvoft 2007)
To be able to perform its functions, a gene needs to be expressed. The process of
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gene expression allows the information from a gene to be used in the synthesis of a
functional gene product such as a protein molecule. Gene expression is of high impor-
tance because by controlling which genes are expressed and which are not expressed
in a given scenario, a cell can decide its phenotype and which proteins to synthesis.
The process of gene expression involves several steps as shown in figure 2.6.
A section of the DNA is first transcribed and then translated. This section is
called the transcription unit. Just above the transcription unit there is a sequence of
nucleotides which defines where the transcription unit begins. This is known as the
promoter region.
2.1.6 Transcription
Transcription is the process by which the information contained in a section of DNA
(a gene) is transferred to a newly assembled piece of RNA. It is facilitated by RNA
polymerase and transcription factors (described in section 2.2). In eukaryotic cells
protein encoding transcripts (pre-mRNA) must be processed further in order to ensure
translation.
2.1.7 Translation
In translation, messenger RNA (mRNA) produced by transcription is decoded by
ribosomes to produce a specific amino acid chain, or polypeptide, that will later fold
into an active protein molecule.
2.1.8 Putting it all together
So far in this section we have seen that, the genetic information that is passed on
from parents to offspring in most living organism is stored in DNA. Genes are a
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unit of heredity, and the entire genome of an organism could contain thousands of
genes. An individual gene is usually a small stretch of DNA, that when expressed,
codes for a specific protein. The process of gene expression involves several steps,
namely transcription, splicing, and translation. The final product of gene expression
is commonly a functional protein molecule. This way, the information that was passed
on from the organism’s parents gets expressed and performs real functions in the
organism.
2.1.9 Selective gene expression
Not every gene is expressed in all cells at all times. By controlling which genes
are active, a cell can take on special characteristics and respond to its environment.
Muscle cells and neurons have the same DNA, but perform different functions because
they express different sets of genes. Transcription factors are one of the mechanisms
to regulate which genes are expressed. In the nucleus, the DNA is condensed in the
chromatin. In places close to where genes are being expressed, there are often zones of
naked DNA. Transcription factors bind to these naked DNA sequences and regulate
gene expression (Lyons 2012).
2.2 Transcription Factors
As mentioned above, transcription factors play a part in the regulation of gene expres-
sion. Transcription factors are protein molecules that bind to a specific DNA sequence.
Once bound to the matching DNA sequence, the transcription factor molecule can
promote or block the transcription of a nearby gene. The location where the tran-
scription factor attaches itself to the DNA is called the transcription factor binding
site. After binding itself the transcription factor regulates a gene that is spatially
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near the binding location, for example, by making it easier for the RNA polymerase
to attach to the gene’s promoter region. In most cases the gene lies downstream to
the transcription factor binding site but in some cases, due to the complex nature of
the three dimensional structure of the chromatin, a transcription factor can regulate
a gene that is thousands of base pairs away but is close to the binding site in three
dimensional space.
By promoting (as an activator), or blocking (as a repressor), the recruitment of
RNA polymerase during transcription, transcription factors regulate the level of gene
expression. RNA polymerase is the enzyme that performs the transcription of genetic
information from DNA to RNA. Some transcription factors perform this function with
other proteins in a protein complex while some do it alone.
Figure 2.7: Transcription factors working as activators (Kelvinsong 2012)
A demonstration of how these proteins affect the level of gene expression is given
in figure 2.7. In this figure, several transcription factors are working together to create
a protein complex that makes it easier for RNA polymerase to attach to the promoter
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region and start transcribing the gene. The gene that is being regulated here is located
in a distant part of the DNA but due to the three dimensional folding of DNA in the
chromatin, it is spatially close to the transcription factor binding site.
By regulating the gene expression, transcription factors enable different cells to
perform different functions. For example, different genes are turned on in liver cells
than those in skin cells and different genes are turned on in cancer cells than in healthy
cells. Through the action of transcription factors, the various cells of the body, which
all have the same genome, can function differently.
Roughly 8% of genes in the human genome encode transcription factors (Broad
2014). They play important roles in development, the sending of signals within the
cell, and the events in a cell that lead to division and duplication, known as the cell
cycle. Several human diseases are linked to mutations in transcription factors, such
as hearing loss, congenital heart disease, and cancer (Villard 2004; Peters et al. 2002;
Schott et al. 1998).
2.3 Biological Pathways
A biological pathway is a series of actions among molecules in a cell that leads to a
certain product or a change in that cell. A pathway can trigger the assembly of new
molecules, such as a lipids or proteins. Pathways can also turn genes on and off, or
spur a cell to move. Some of the most common biological pathways are involved in
metabolism, the regulation of genes, and the transmission of signals.
2.4 ChIP-X Experiments
Several in vivo experimental technologies such as ChIP-chip (Iyer et al. 2001), ChIP-
seq (Johnson et al. 2007), ChIP-PET (Wei et al. 2006) and DamID (Peric-Hupkes
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et al. 2010) provide details about possible binding sites for transcription factors at
a genome-wide level. These four methods together are referred to as ChIP-X. The
sites discovered using the ChIP-X methods are near genes and are found when the
chromatin structure of a specific cellular state allows binding of a particular tran-
scription factor. This means that unlike possible binding sites found using in vitro
approaches, the possibility of these sites to have actual biological significance is much
higher. Results from such experiments report the binding of specific transcription fac-
tors to DNA in proximity of a target gene’s location. Such experiments commonly list
hundreds to thousands of potential regulatory interactions (Lachmann et al. 2010).
2.5 Gene Expression Profiling
Gene expression profiling is the measurement of the abundance level (the expression)
of thousands of transcripts at once, to create a global picture of cellular state. These
profiles can, for example, distinguish between cells that are actively dividing, or show
how the cells react to a particular treatment.
A DNA microarray (also commonly known as a DNA chip or biochip) is a collection
of microscopic DNA spots attached to a solid surface. Scientists use DNA microar-
rays to measure the expression levels of large numbers of genes simultaneously, or
to genotype multiple regions of a genome. Each DNA spot contains segments of a
specific DNA sequence, known as probes (or reporters or oligos). These can be a
short section of a gene or other DNA element that are used to hybridize a cDNA
or cRNA (also called anti-sense RNA) sample (called target) under high-stringency
conditions. Probe-target hybridization is usually detected and quantified by detection
of fluorophore-, silver-, or chemiluminescence- labelled targets to determine relative
abundance of the targets in the sample. RNA-seq refers to the use of high-throughput
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sequencing technologies to sequence cDNA in order to get information about a sam-
ple’s RNA content. The technique has been rapidly adopted in studies of diseases like
cancer.
2.6 Pathway Analysis of Gene Expression Data
Gene expression profiling experiments allow biologists to measure the activity lev-
els of genes. The data that is generated from such experiments usually is several
megabytes long. For example in (Emery et al. 2009) and (Lavery et al. 2008), the
research teams have performed typical gene expression profiling experiments and the
data after refinement is 88 MB and 21.7 MB in size respectively. To derive useful
information from this large quantity of data is a challenge. In the last decade or so,
as experiments of such nature have gained popularity, several approaches have been
devised to help researchers understand the meaning of this data and to determine the
biological activities taking place in the cells under observation.
This thesis is in the research area of facilitating the researchers who are performing
such experiments to understand the biological processes that are active in their studied
cellular state. It is done by performing statistical tests on the data obtained from high
throughput gene expression profiling experiments. Several individual research groups
have made important contributions to this field and this project built upon the work
that has been done so far. In the following sections, we discuss all those techniques
and databases that are related to this project.
2.7 Gene sets formation
Individual genes are annotated based on their functions, position and other charac-
teristics. For example, functional annotation for a gene can be its association with
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a particular function in a metabolic pathway. Any information about the function
of this gene is a functional annotation of the gene. These annotations are stored in
publicly available databases. Using these publicly available gene annotations it is
possible to create gene sets by taking all the genes that have a common annotation
and clubbing them together. Usually every biological pathway, such as metabolic or
signaling pathways, are associated with certain genes. Thus, by clubbing together
genes based on their functions, we can connect biological processes or pathways to
sets of genes. An example of such a gene set could be the KEGG pathway Glycerolipid
metabolism (hsa00561) (Kanehisa and Goto 2000). Based on published studies, there
are 49 genes associated with the pathway (Norbeck et al. 1996; Karlsson et al. 1997;
Berg et al. 2001). These genes form the glycerolipid metabolism gene set.
2.8 Enrichment Analysis (Pathway Analysis)
High-throughput gene expression profiling techniques, such as DNA microarray and
RNA-Seq, allow researchers to simultaneously measure genome-wide levels of gene ex-
pression under specific biological conditions. Statistical approches such as limma (Smyth
2005) and edgeR (Robinson, McCarthy, and Smyth 2010) are then used to identify
differences in gene expression between two or more conditions. Enrichment analysis or
pathway analysis is an analytical approach to interpret the results of a gene expression
profiling experiments with respect to gene sets. It is the process with which we as-
sociate observed changes in gene expression with cellular functions and/or metabolic
pathways. Without such an analytical process, it will be very difficult to comprehend
which biological pathways are most active in the particular case under study.
Gene expression profiling experiments usually generate a list of differentially expressed
genes. Here is an example of how the data that is obtained from such an experiment
24
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looks (Lavery et al. 2008).
EntrezID 8hCont1 8hTrt 8hCult1 8hCont2 8hTrt 8hCult2
10000 6.666482 6.727039 7.859644 7.888743
10001 9.874859 9.873068 9.838792 9.757909
10002 5.524512 5.651697 5.299609 5.146715
10003 4.604491 4.661876 4.790255 4.705559
10004 7.904135 7.883218 8.00505 7.962769
...
...
Table 2.1: Expression profiling data sample
Such a list can be very useful in identifying genes that may have roles in a par-
ticular phenomena or phenotype. However, for many researchers this list would not
be sufficient in providing insight into the underlying biology of the condition being
studied. To individually study each gene and interpret the meaning would be a very
complex and time consuming process. Therefore, categorizing the genes based on
their common functional annotation helps in two ways.
Reduced complexity By grouping the genes into sets of genes, with each gene
set targeting a specific pathway or function, the complexity is reduced to just a few
hundred pathways for the experiment.
Higher explanatory power Pathways that have different activity levels between
two conditions would generally have a higher explanatory power than just a list of
genes would (Glazko and Emmert-Streib 2009).
Hence the lower complexity and higher explanatory power of enrichment analysis
has made it a de-facto in post gene expression analysis. Broadly, there are three
different approaches for performing enrichment analysis (Khatri, Sirota, and Butte
2012). They are :
• Over-Representation Analysis (ORA) approach
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• Functional Class Scoring (FCS) approach.
• Pathway Topology (PT) approach.
We look at them one by one in the following sections.
2.8.1 Over-Representation Analysis (ORA) Approach
The growth in the popularity of High-throughput sequencing, and also the develop-
ment of public gene set repositories such as Gene Ontology (GO) or Kyoto Encyclope-
dia of Genes and Genomes (KEGG), fueled the immediate need for functional analysis
of microarray gene expression data. To tackle these problems the Over-Representation
Analysis (ORA) approach was devised.
From the expression levels observed in the sequencing experiment, a list of signifi-
cant genes that were over-expressed or under-expressed is created. To create this list,
an arbitrary cut-off p-value is set. For example, a researcher may say that all genes
that have a p-value less than, or equal to, 0.05 qualify as significant genes. Next,
for each pathway (or gene set) the numbers of genes that are present in this list are
counted. Then, by using statistical analysis techniques, such as tests based on the
hyper geometric, chi-square, or binomial distribution, it is determined whether more
genes belonging to the gene set are present in the list than expected by chance.
This is a very simple technique, but it sheds some light on the gene sets that are
under or over expressed. ORA has a few shortcomings too, as discussed next.
Limitations of Over-Representation Analysis (ORA) Approach
Even though the ORA approach is the most popular approach, it has several short-
comings.
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Firstly, the statistical tests (e.g., hyper geometric distribution, binomial distribu-
tion, chi-square distribution, etc.) ignore the measurements found for the genes in
the gene expression experiments. As this data is ignored, all the genes that make the
list are treated equally despite their varying levels of expression. The list of signifi-
cant genes is generated based on an arbitrary threshold and the individual genes that
do not make the threshold are discarded. Genes whose expression levels fall in the
border of the threshold also have some significance but are totally ignored. This is a
disadvantage of having a hard cutoff threshold.
Secondly, one of the goals of gene expression analysis is to understand how interac-
tions between various gene products occur as the levels of gene expression changes. By
considering that all the genes are independent, ORA significantly reduces its ability to
analyze complex biological interactions that include several gene products. Because
the ORA techniques consider all genes as equal and independent, it fails to provide
any insight in this regard.
Finally, this approach works with the assumption that all the pathways are in-
dependent to each other, which is not true. For example, in signaling pathways in
KEGG, there is a presence of growth factors that activate the MAPK signaling path-
way. This signaling pathway in turn activates the cell cycle pathway. ORA methods
do not account for such inter-pathway interactions and dependences.
2.8.2 Functional Class Scoring (FCS) Approach
In most biological systems, significant effects on pathways can be caused by large
changes in individual genes, but they can also be caused by weaker coordinated
changes in the expression levels of several functionally related genes. By clubbing
such related genes into a gene set such that a gene set represents a biological path-
way, we can detect such effects. Almost all the FCS based methods have mainly three
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steps:
Step 1: Calculate Gene Level Statistic
First a gene level statistic is computed from the molecular measurement data
obtained from high-throughput expression analysis experiments such as DNA
microarray or RNA-Seq. This is done by calculating differential expression for
each of the genes. Several statistical methods, such as correlation of molecular
measurements with phenotype (Pavlidis et al. 2004), Q-statistic (Goeman et al.
2004), signal-to-noise ratio (Subramanian et al. 2005), t-statistic (Tian et al.
2005) or Z-score (Kim and Volsky 2005) can be used to represent the expression
levels.
Step 2: Calculate pathway level statistics
Next, gene level statistics for all genes in a given gene set are aggregated into a
single pathway level statistic. There are several statistical methods to do this but
some of the more common ones are Kolmogorov - Smirnov (Smirnov 1944), the
Wilcoxon rank sum test (Mann, Whitney, et al. 1947), or to take the sum, mean
or median of the gene level statistics. Whatever method is chosen to implement
this, it’s power can depend on factors such as the proportion of the genes present
in the pathway that were differentially expressed, the actual size of the pathway
(i.e. the number of genes present in the pathway) and the amount of correlation
that exists between the various genes in the pathway. Even though multivariate
statistics should show better results as they also account for inter-dependencies
among genes, it has been observed that for higher cut-offs (pV alue ≤ 0.001), the
uni-variate statistics show more power, and for less stringent cut-offs (pV alue ≤
0.05) the uni-variate statistics show equal power (Khatri, Sirota, and Butte
2012).
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Step 3: Assessing statistical significance of the pathway level statistic
In this step the statistical significance is computed by using a null hypothe-
sis. There are mainly two ways to do the testing: competitive null hypothesis
testing and self-contained null hypothesis testing. In the former method, class
labels (i.e. phenotypes) for each sample are permuted, and comparison is made
between the set of genes in a given pathway with itself. In the latter method,
gene labels are permuted for each pathway, and comparisons are made between
the set of genes that are in the pathway, with the set of genes that are not in
the pathway. The size of the gene sets remains the same.
Advantage of using FCS
Some of the limitations described above related to using the ORA approach have been
addressed in the FCS approach. This helps FCS provide better results and deeper
insight into the underlying biology of any given condition than those provided by
ORA. For example, FCS does not require any arbitrary cut-off threshold for dividing
the genes into significant and non-significant groups. It uses all the available molecular
measurements for its analysis. FCS uses the molecular measurement information to
detect coordinated changes in expression of genes in some pathways. By detecting
such coordinated changes, FCS can give us information about dependence between
genes.
Limitations to FCS
FCS analyzes each pathway independently, hence a problem arises when a single gene
is part of multiple pathways. In such a case, a given gene might be over-expressed
because it is playing an important role in a particular pathway, but this expression
level will be considered while evaluating the pathway level statistic of other pathways
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that the gene is a part of. Another limitation arises when the statistical method used
to implement FCS is a rank based method. In such a case, the value obtained in the
experiment is not considered in the analysis, but only the rank assigned is considered.
2.8.3 Pathway Topology (PT)-Based Approach
Pathway topology is the newest technique available for performing enrichment analy-
sis. It is similar to FCS, except for how pathway topology based-approaches compute
the gene level statistics. Several publicly available pathway knowledge bases hold
information about gene products that interact with each other, how those products
interact and where they interact in a given pathway. ORA and FCS do not utilize this
knowledge. An example of a PT-based approach is ScorePAGE proposed by (Rah-
nenfuhrer et al. 2004). ScorePAGE computes similarity between each pair of genes
in a pathway. The similarity is measured by calculating the correlation or covariance
between the two genes. The similarity score is comparable to the gene level score
in FCS based approaches. Then, these scores are averaged to arrive at the pathway
level statistics. However, ScorePAGE divides the similarity score with the number
of reactions needed to connect the two genes in the pathway. This strategy assigns
varying weights to the pairwise similarity scores.
Limitations
Some of the common limitations with this strategy are:
• Pathway topology depends upon the cell type and the condition being studied.
Hence this information is not readily available and is usually fragmented in
various knowledge bases. As the annotation becomes more comprehensive and
complete, these approaches are expected to perform better.
30
2.8. ENRICHMENT ANALYSIS (PATHWAY ANALYSIS)
• No existing PT-based approach can collectively model and analyze high-throughput
data as a single dynamic system.
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Chapter 3
Methodology and Implementation
3.1 Motivation
In the modern day world a plethora of data is produced everyday in laboratories per-
forming high throughput experiments such as DNA Sequencing and Gene Expression
Profiling. Trying to analyze and understand the mechanisms of the biological pro-
cesses under study is a non-trivial task. To extract knowledge from this data there
is a need for new computer programs to perform analytics and help interpret this
growing amount of data.
Some of the common questions that arise after any RNA sequencing or DNA
microarray experiment are: what biological pathways were affected in the sample,
and which transcription factors were regulating these biological pathways. Providing
answers to these questions can help researchers to make new discoveries or provide
direction to their future research.
Currently there are programs to identify the biological pathways that are getting
affected. As discussed in Khatri et al (Khatri, Sirota, and Butte 2012) programs such
as Gage (Luo et al. 2009) can identify the gene sets that are over or under expressed
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in the sample by statistical testing. There are also programs such as ChEA (Kou et
al. 2013) as described in the previous chapter that provide information about which
transcription factors have their targets over-represented in a list of genes. Presently
though, there is no such program that provides the full picture by predicting which
transcription factor is actually regulating the pathways that are most affected in the
study sample.
In this project, we combine the results of gene set enrichment analysis (FCS)
and Chip-X data driven analysis to make predictions that tell the researcher which
transcription factors might regulate pathways affected in the sample being studied.
3.2 Overview of the system
The software system that we built to materialize our idea had to perform several
tasks. First, it should quantify to what degree a given transcription factor regulates
any particular gene set. To achieve this, we performed a functional class scoring on
the data obtained from the ENCODE project. Second, the software should identify
which gene set was most affected in a given experiment. After conducting an exper-
iment, researchers can use this software to perform functional class scoring on the
data obtained from their experiment to reveal the biological pathways that were most
affected. Finally, the system should combine the results of the above two parts to
arrive at the final results. The final results will be a list of transcription factors and
gene sets that are playing an important role in the phenomena under study.
We named our system REPA for Regulation Expression Pathway Analysis.
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3.3 REPA description
We will now look at the inputs to the system. Then, we will see each module in a
greater detail. The modules of the system are as follows:
• Linking transcription factor binding sites with promoter regions of known human
genes
• Creating the Regulation Database
• Expression Analysis
• Combining Regulation and Expression Results
3.3.1 Inputs to the system
There are mainly three inputs to the system.
Gene sets from gene annotation databases
As described in the previous chapter, a gene set is a group of genes that has some
common functional annotation. A gene set may represent a biological pathway and
include all the genes that play a role in that pathway.
For this project we gather our gene sets from two sources:
• Molecular Signatures Database or MSigDB
MSigDB (Subramanian et al. 2005; Liberzon et al. 2011) is a collection of anno-
tated gene sets that were made publically available by various research groups
such as Reactome (Vastrik et al. 2007), Biocarta (Nishimura 2001), Gene On-
tology (Ashburner et al. 2000), Gene Arrays, KEGG (Kanehisa and Goto 2000;
Kanehisa et al. 2014) and more.
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MSigDB contains gene sets that are kept classified in six collections.
H Hallmark gene sets
Hallmark gene sets summarize and represent specific well-defined biological
states or processes and display coherent expression. These gene sets were
generated by a computational methodology based on identifying gene set
overlaps and retaining genes that display coordinate expression (Total 50
gene sets).
C1 Positional gene sets
These are gene sets corresponding to each human chromosome and each
cytogenetic band that has at least one gene. These gene sets are helpful
in identifying effects related to chromosomal deletions or amplifications,
dosage compensation, epigenetic silencing, and other regional effects (Total
326 gene sets).
C2 Curated gene sets
These are gene sets collected from various sources such as online pathway
databases, publications in PubMed, and knowledge of domain experts. The
gene sets in this group can be further classified into the following groups
(Total 4725 gene sets).
CGP: chemical and genetic perturbations These gene sets represent
expression signatures of chemical and genetic perturbations. For each
perturbation there is usually two sets: one set consisting of genes that
show increase in expression levels (XXX UP ) and another set consist-
ing of genes that show lower expression levels denoted by (XXX DOWN)
(Total 3395 gene sets).
CP: Canonical pathways These gene sets are from pathway databases.
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These are usually compiled by domain experts and are canonical rep-
resentation of any given biological process (Total 1330 gene sets).
CP:BIOCARTA: BioCarta gene sets These are genes derived from
BioCarta pathway database (Nishimura 2001) (Total 217 gene sets).
CP:KEGG: KEGG gene sets Genes derived from KEGG pathway database
(Kanehisa and Goto 2000; Kanehisa et al. 2014) (Total 186 gene sets).
CP:REACTOME: Reactome gene sets Genes derived from Reactome
pathway database (Vastrik et al. 2007) (Total 674 gene sets).
C3 Motif gene sets
Gene sets that contain genes that share a cis-regulatory motif that is con-
served across the human, mouse, rat, and dog genomes (Xie et al. 2005)
(Total 836 gene sets).
MIR: microRNA targets Gene sets that contain genes that share a 3’-
UTR microRNA binding motif (Total 221 gene sets).
TFT: transcription factor targets Gene sets that contain genes that
share a transcription factor binding site defined in the TRANSFAC
database (version 7.4) (Wingender 2008). Each of these gene sets is
annotated by a TRANSFAC record (Total 615 gene sets).
C4 Computational gene sets
Computational gene sets defined by mining large collections of cancer-
related microarray data (Total 858 gene sets).
C5 GO gene sets
These are the gene sets that are named after GO terms and contain genes
annotated by that term (Total 1454 gene sets). The gene sets in this group
can be further classified into the following groups.
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BP: GO biological process Gene sets derived from the Biological Pro-
cess Ontology (Total 825 gene sets).
CC: GO cellular component Gene sets derived from the Cellular Com-
ponent Ontology (Total 233 gene sets).
MF: GO molecular function Gene sets derived from the Molecular Func-
tion Ontology (Total 396 gene sets).
C6 Oncogenic signatures
These gene sets represent signatures of cellular pathways which are of-
ten dis-regulated in cancer. The majority of signatures were generated
directly from microarray data from NCBI GEO (Edgar, Domrachev, and
Lash 2002) or from internal unpublished profiling experiments which in-
volved perturbation of known cancer genes. In addition, a small number of
oncogenic signatures were curated from scientific publications (Total 1454
gene sets).
C7 Immunologic signatures
Gene sets that represent cell states and perturbations within the immune
system (Total 1454 gene sets).
• KEGG: Kyoto Encyclopedia of Genes and Genomes
Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www.genome.jp/
kegg/ or http://www.kegg.jp/) is a database that provides manually curated
gene sets (Kanehisa and Goto 2000; Kanehisa et al. 2014). KEGG collects infor-
mation on functional annotations of various DNA elements and integrates this
information. Genes from completely sequenced genomes are linked to higher-
level systemic functions of the cell, the organism and the ecosystem. Then
this information is used to create a knowledge base for organizing experimental
37
3.3. REPA DESCRIPTION
knowledge in computable forms; namely, in the forms of KEGG pathway maps.
Any KEGG pathway includes a list of all the genes which play a functional
role in the pathway and also other details such as the pathway map and any
diseases linked with this pathway. The genes in a given pathway form a gene
set. In REPA we used the gene sets from KEGG along with the gene sets from
MSigDB. We included directly KEGG pathways as gene sets, as we noted that
MSigDB does not include the most recent version of the KEGG.
We represent gene sets in the format that is used by MSigDB. Namely first column
gives the name of the gene set. The second column is not used by the program but
specifies a URL that gives more information about the specific gene set. After that
we have a list of entrez ids that specify the genes that are present in the gene set.
The file is a tab delimited text file without headers. For example, table 3.1 shows the
format of a sample gene set.
Gene Set Name URL Entrez IDs of members
KEGG STEROID BIOSYNTHESIS
http://www.broadinstitute.org/
gsea/msigdb/cards/
KEGG STEROID BIOSYNTHESIS.html
6646,4047,6713,10682,
1595,1717,1594,1718,
51478,6307,2222,6309,
3988,1056,7108,50814,
8435
...
...
...
Table 3.1: Sample Gene Set
Transcription Factor Binding Data (TFBD)
As described in the previous chapter in section 3.4.1 one of the goals of the public
research project Encyclopedia of DNA Elements or ENCODE (Consortium et al.
2012) was to identify the transcription factor binding sites. The data produced under
this project from numerous Chip-Seq (Johnson et al. 2007) and Chip-Chip (Iyer et al.
2001) experiments provide information about the binding sites of 160 transcription
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factors in 44 cell lines. This data was then processed and used by ChEA2 (Kou et al.
2013). ChEA2 also made the processed data freely available for download on their
website (Kou 2014).
The ENCODE data compiled by ChEA2 includes 920 experiments done in 44
cell-lines profiling 160 transcription factors for a total of approximately 1.4 million
transcription-factor / target-gene interactions (Kou et al. 2013). This data is given
in the bed format which includes the transcription factor, cell line, start and end of
peaks, score and signal. The score and signal values are directly proportional to the
strength of the binding between DNA and the given transcription factor at any given
site. The score value is derived from the signal and lies between 0 and 1000 and it is
proportional to the maximum signal strength. We use the signal strength as input to
our algorithm.
Genomic positions of human genes
To link the transcription factor binding sites to the genes that the transcription fac-
tors likely regulate, we needed the locations of both the transcription factor binding
sites and the genes. As mentioned above, we got the ENCODE transcription factor
binding sites data from ChEA2. For a list of all human genes and their position we
used Ensembl’s Biomart (Kinsella et al. 2011) website http://www.ensembl.org/
biomart/martview/. Using this website we gathered the genomic positions of all
human genes. The version that was used was Ensembl Release version 71 and the
data set was Homo sapiens genes (GRCh37.p10) (may 21, 2013). We included all
genes coding for lincRNA, miRNA and proteins.
A sample of the data downloaded from Ensembl’s biomart website is given in
table 3.2.
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Ensembl Gene ID Associated Gene Name Chromosome Name Strand Gene Start (bp)
ENSG00000248425 AC006296.2 4 1 14392063
ENSG00000236437 AP001891.1 11 -1 116367616
ENSG00000240567 RP11-3P17.4 3 1 161144215
ENSG00000235357 RP1-159G19.1 6 -1 80513300
...
...
...
...
...
Table 3.2: Ensembl Biomart Human Gene List
Gene expression profiling experiment data
After processing the results obtained from a high throughput gene expression profil-
ing experiments such as DNA micro-array or RNA-seq a list with all the genes in the
experiment with their corresponding level of activity is generated. To represent the
gene level activity various types of statistics can be used. Some of the popular statis-
tics user are log fold change, Z-statistic, t-statistic, etc. Table 3.3 gives an example
of how the data looks.
Entrez ID logFC AveExpr t-statistic P.Value adj.P.Val
5228 4.066771195 8.984909943 30.01850012 1.75E-06 0.030867069
8200 -2.937752131 9.096127188 -22.30635557 6.85E-06 0.060528957
3400 3.107500295 8.990624466 18.99550122 1.43E-05 0.066519298
133 -3.11990311 9.026165624 -17.69540658 1.98E-05 0.066519298
Table 3.3: Sample gene expression profiling experiment data
3.3.2 Step 1: Linking transcription factor binding sites with
promoter regions of human genes
As discussed in (Kristiansson et al. 2009) “A gene’s promoter region is traditionally
(if loosely) defined with respect to its transcription start site (TSS): 1000-3000 base
pairs upstream, and 100-300 basepairs downstream.” In our project we focus on
cis-regulated regions which are within 3000 base pairs upstream of the genes as the
majority of the binding sites are located there. We ignored the enhancer regions which
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are binding sites but typically at a much larger distance from the TSS.
We found all such instances where in the ENCODE data, a transcription factor
binding site existed within 3000 base pairs upstream of a gene’s TSS.
Inputs to this part were the bed file with the location of the DNA - transcription
factor binding peaks and the bed file with the genomic coordinates from the gene’s
transcription start site to 3000 base pairs upstream for all human genes as described in
section 3.3.1. We used Bedtools (Quinlan and Hall 2010) to accomplish this. Intersect
command in Bedtools was used to find those promoter regions where a binding event
occured. The command used was as follows:
i n t e r s e c tBed −a encode . bed −b geneL i s t . bed −wo
The −wo flag writes side by side the original A and B entries plus the number of
base pairs of overlap between the two features.
3.3.3 Step 2: Creating the Gene Set - Transcription Factor
Binding Database
The goal of this step is to associate a transcription factor with given gene sets based
on the binding strength of that transcription factor with the promoter region of the
genes in each gene set. In other words we want to find out whether a transcription
factor may regulate a given gene set. To achieve this we ran a functional class scoring
with the transcription factor binding signals associated to human genes and the gene
sets obtained from MSigDB and KEGG.
As described in the previous chapter, a functional class scoring approach has three
steps. First is to calculate the gene level statistic. Next step is to find a gene set level
statistic using the gene level statistic and finally using null hypothesis testing we find
out the statistical significance of the gene sets.
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A step by step description of the process follows.
Inputs
1. Gene sets in the format described in the section 3.3.1.
2. Transcription factor binding data from the output obtained in step 1 de-
scribed in section 3.3.2.
Step 2.1: Parsing and loading input files The two input files are parsed and
loaded in memory. A hash table is used to store the data to quickly access
the values based on transcription factor name and the gene’s Entrez Id.
Steps 2.2 through 2.6 are performed for each transcription factor - gene set pair.
Step 2.2: Map TFBSs to strongest signal Get the signal values from the tran-
scription factor binding sites database for each of the gene in the gene set. If
multiple values exist from different cell lines, the maximum value is considered.
If there are values for at least 5 genes in the gene set we proceed to the next
step else we skip to the next gene set - transcription factor pair.
Steps 2.3 and 2.4 are executed 1000 times.
Step 2.3: Generate vector with random signal values To run the permutation
test, we first generate a gene set of randomly selected genes of the same size as
that of the real gene set. We collect the signal values for this randomly chosen
gene set from the transcription factor binding database as done in step 2.2 for
the real gene sets.
Step 2.4: Statistical hypothesis testing We use the following three statistical
tests in our program with the real gene set values and the random gene set
values as input.
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Two-sample pooled test (ALGLIB project ; Broad 2014)
This test checks hypotheses about the fact that the means of two random
variables X and Y which are represented by samples xS and yS are equal.
In our case xS represents the signals from real gene sets we found in step
2.2 and yS represents the randomly selected signal in the step 2.3. The test
works correctly under the following conditions:
• Both random variables have a normal distribution
• Dispersions are equal (or slightly different)
• Samples are independent.
During its work, the test calculates t-statistic:
t = xS−yS√∑
(xi−xS)2+
∑
(yi−yS)2
Nx+Ny−2
(
1
Nx
+ 1Ny
)
NX and NY are the sizes of X and Y respectively.
Note 1 If X and Y have a normal distribution, the t-statistic will have
Student’s distribution with NX+NY −2 degrees of freedom. This allows the
use of the Student’s distribution to define a significance level corresponding
to the value of the t-statistic.
Note 2 If X or Y are not normal, t will have an unknown distribution
and, strictly speaking, the t-test is inapplicable. However, according to the
central limit theorem, as the sample sizes increase, the distribution of t
tends to be normal. Therefore, if sample sizes are big enough, we can use
the t-test even if X or Y is not normal. But there is no way to find what
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values for NX and NY are big enough. These values depend on how X and
Y deviate from the normal distribution.
After running this test we store the right-tailed p-value. The null hypoth-
esis for the right-tailed test is that the mean of yS is less than or equal to
the mean of xS.
Two-sample unpooled test (ALGLIB project) Similar to the two-sample
pooled test, this test checks hypotheses about the fact that the means of
two random variables X and Y which are represented by samples xS and
yS are equal. The test works correctly under the following conditions:
• Both random variables have a normal distribution
• Samples are independent.
Unlike the previous test, for this test, dispersion equality is not required.
During its work, the test calculates the t-statistic:
t = xS−yS√
V ar(xS)
NX
+
V ar(yS)
NY
If X and Y have a normal distribution, the t-statistic will have Student’s
distribution with DF degrees of freedom:
DF = (NX−1)(NY−1)
(NY−1)c2+(NX−1)(1−c2)
c =
V ar(XS)
NX
V ar(XS)
NX
+
V ar(XS)
NY
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This allows the use of the Student’s distribution to define the significance
level corresponding to the value of the t-statistic. Note 2 from the two
sampled pooled test section is also applicable to this test.
Mann-Whitney U test The Mann-Whitney U-test (Mann, Whitney, et al.
1947; McKnight and Najab 2010; Bochkanov and Bystritsky 1947) is a
non-parametric method which is an alternative to the two-sample Student’s
t-test. This test is used to compare medians of non-normal distributions
X and Y . The test works correctly under the following conditions:
• X and Y are continuous distributions (or discrete distributions well-
approximating continuous distributions)
• X and Y have the same shape. The only possible difference is their
position (i.e. the value of the median)
• The number of elements in each sample is not less than 5
• The samples are independent
• Scale of measurement should be ordinal, interval or ratio (i.e. test
could not be applied to nominal variables)
Here is a simple step by step description of how the Mann-Whitney U test
works:
• Both samples (having sizes N and M) are combined into one array
which is sorted in ascending order keeping track of which sample the
element had come from.
• After sorting, each element is replaced by its rank (its index in array,
from 1 to N +M).
• Then the ranks of the first sample elements are summarized and the
U-value is calculated using the following formula:
45
3.3. REPA DESCRIPTION
U = N ×M + N(N+1)2 −
∑
xi
Rank(xi)
The mean of U equals 0.5 × N ×M . If U is close to this value, the
medians of X and Y are close to each other. If we know distribution
quantiles, we can get the significance level corresponding to the value
of U .
• For a big enough N and M , U could be approximated by the normal
distribution with a mean of 0.5×N ×M and a standard deviation of
σ =
√
N×M(N+M+1)
12
The p-value is calculated from the mean and standard deviation.
All the three tests mentioned above namely two-sample pooled test, two-sample
unpooled test and Mann-Whitney U-test returns three p-values:
p-value for two-tailed test The null hypothesis here is that the medians for
the two samples are equal.
p-value for left-tailed test The null hypothesis here is that the median of yS
is greater than or equal to the median of xS.
p-value for right-tailed test The null hypothesis is that the median of yS is
less than or equal to the median of xS.
Step 2.5 For three pre-determined thresholds of significance namely 0.05, 0.01 and
0.001 we count number of times the mean / median of the values of the actual
gene set is to the right of the mean / median of the values of the random gene
set with a p-value of:
• less than 0.001
• between 0.01 and 0.001
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• between 0.05 and 0.01
• greater than 0.05
Transcription Factor E2F6
Gene set name DOANE BREAST CANCER CLASSES UP
Total genes in the gene set 72
Genes for which values were found 14
Pooled tTest [< 0.001] 11
UnPooled tTest [< 0.001] 7
MWU test [< 0.001] 5
Pooled tTest [< 0.01] 74
UnPooled tTest [< 0.01] 75
MWU test [< 0.01] 70
Pooled tTest [< 0.05] 238
UnPooled tTest [< 0.05] 237
MWU test [< 0.05] 249
Pooled tTest [Remaining] 677
UnPooled tTest [Remaining] 681
MWU test [Remaining] 676
Pooled tTest Average p-value 0.1937
UnPooled tTest Average p-value 0.194217
MWU test Average p-value 0.18896
Genes in gene set for
which values were found 347, 253190, 51181 . . . . . . . . . . . . . . . . . . . . . . . .
Table 3.4: Sample of the gene set - transcription factor binding database
Results After running the program for all the transcription factors and gene sets
available, the generated results are as shown in table 3.4. Due to space con-
strains, the columns are presented as rows and rows as columns.
3.3.4 Step 3: Expression Analysis
The purpose of this step is to identify which gene set is over-expressed or under-
expressed in the given biological sample. To achieve this goal, we used a functional
class scoring approach.
The inputs to the system are as follows:
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1. Gene sets in the format described in the section 3.3.1
2. High throughput Gene expression profiling experiment data in the format de-
scribed in section 3.3.1.
Step 3.1: Parse and load input data
First the two data files i.e. the expression levels and gene set database are read
and loaded in the memory.
The following steps are executed for each available gene set in the database.
Step 3.2: Get expression levels for member genes of the gene set
For each of the genes present in the selected gene set, their corresponding values
are retrieved and stored in a vector.
If the number of values found is greater than 5, proceed with the following steps.
Step 3.3: Create a random value vector of equal size
Here we select values from the expression levels files and insert them into a new
vector. The number of values randomly selected and inserted are equal to the
number of values found in the previous step.
Step 3.4: Running the statistical hypothesis tests
To understand the statistical significance of the values found in step 2, we com-
pare them with the randomly generated values from step 3. We use the following
three statistical hypothesis tests for this:
1. Two-sample pooled test
2. Two-sample unpooled test
3. Mann-Whitney U test
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This step is similar to the step 4 in section 3.3.3 and the detailed description of
the tests are also given in the same section.
Results After running the tests for all the available gene sets, we arrive at p-values
for each gene set for the particular case. We can conclude that the gene sets
with the lowest p-values are either over-expressed or under-expressed. In either
case their behavior is different from what is expected hence it can be concluded
that there is a strong likelihood that the gene set is playing an important role
in the cellular condition under study.
3.3.5 Step 4: Combining two p-values
From the two previous steps we have the following information:
From Step 2 A p-value quantifying the level of binding a transcription factor has
on a gene set.
From Step 3 A p-value representing the level of perturbation shown by any given
gene set in the experimental condition under study.
The next step is to combine the two p-values to obtain another p-value that rep-
resents the likelihood of a transcription factor regulating the gene set in the biological
condition under study.
To achieve this we follow the method suggested in the article titled ‘Combining
p-values via averaging’ (Vovk 2012). In this article, the authors explains an old result
by Ru¨schendorf which shows that the p-values can be combined by scaling up their
average by a factor of two. In our case since the there are only two p-values, we
calculate the combined p-value as below:
pcombined :=
2
K (p1 + p2 + ... + pK)
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with K = 2
3.4 Brief survey of existing approaches for associ-
ating transcription factors to gene lists
The task of associating transcription factors with genes based on specific biological
conditions has been tackled by some researchers. The work done in this field that we
came across has been described and compared with in this section.
3.4.1 ChIP-X Enrichment Analysis (ChEA)
ChEA is a software tool that utilizes ChIP-X experiments data for linking transcrip-
tion factors to gene expression changes by computing over-representation of transcrip-
tion factor targets in an input list of genes. ChEA essentially counts the number of
targets in a list and compares them with the number of targets that were identified
in the database, i.e. an ORA approach of transcription factor targets on an input list
of genes (Lachmann et al. 2010).
ChEA is based on a manually curated database from the literature reporting ChIP-
X experiment results. In this database, each record contains a list of genes potentially
regulated by a specific transcription factor under a specific condition. This database
was then used as the prior knowledge base to analyze mRNA expression data where
enrichment analysis was performed. The current database as of September 2014 has
the following statistics:
• Transcription Factors: 209
• Publications: 237
• Genes: 47197
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• Total Entries: 483786
ChEA is commonly used after a genome-wide gene expression profiling study is per-
formed. The steps that follow are: First, a list of genes that significantly changed their
expression levels is prepared and given as an input to the ChEA software. Next, the
software computes over-representation for targets of transcription factors per study
in the ChIP-X database. To compute statistical enrichment, ChEA implements the
Fisher exact test with Bonferroni’s correction, where the proportions for the test are
the number of genes in the input list, the number of genes identified in the ChIP-X
experiment, the genes that are shared among the two lists, and the number of overall
targets in the ChIP-X database. Finally, ChEA reports a ranked list of ChIP-X exper-
iments that show statistically significant overlap with the input list. Identified genes
from the input list, potentially regulated by a specific transcription factor, are also
connected and visualized as a network, using known protein - protein interactions.
The ENCODE (Consortium et al. 2012; Raney et al. 2011) project was started
with the main purpose of finding the functional elements of the human genome. Along
with assigning function to DNA elements, a big part of the ENCODE project is to
identify the transcription factor binding sites on the entire human genome.
The results from the experiments performed under ENCODE provide us with
details about the location in the genome where a transcription factor binds and also
the intensity of its binding. ChEA2 (Kou et al. 2013) also includes in its database all
ChIP-X experiments from the ENCODE project.
Similarities between ChEA and REPA
The two programs are similar in the following ways:
• Both ChEA and REPA attempt to identify transcription factors regulating a col-
lection of genes thereby predicting likely regulators of biological systems under
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study.
• The data used by both ChEA2 and REPA comes from the ENCODE project.
Differences between ChEA and REPA
• REPA uses a functional class scoring algorithm instead of the over representation
analyses approach used by ChEA. This allows REPA to identify gene sets instead
of transcription factors that may regulate a list of genes that may or may not
be co-functional. By using over representation analyses approach ChEA suffers
from disadvantages arising from using hard cutoffs.
3.4.2 Inferring condition-specific transcription factor func-
tion from DNA binding and gene expression data
‘CRACR’ (McCord et al. 2007) (Combination Rank-order Analysis of Condition-
specific Regulation; pronounced ‘cracker’), derives information about condition-specific
gene regulation and transcription factor activity by combining comprehensive, condition-
independent protein binding microarray (PBM) (Berger and Bulyk 2009) data for a
given TF with gene expression microarray data under a variety of biological condi-
tions. Specifically, CRACR searches for conditions in which differentially expressed
genes are enriched or genes whose upstream intergenic regions (IGRs) contain a pat-
tern to which a transcription factor has significant preference in PBM data. In contrast
to earlier studies, CRACR integrates PBM-derived transcription factor sequence pref-
erence data with gene expression data without imposing arbitrary cut-offs that define
which IGRs are ‘bound’ or which genes are ‘differentially expressed’. In addition,
CRACR uses rank order statistics, which facilitates comparison of gene expression
data from different microarray platforms.
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To predict the condition specific functions of yeast Saccharomyces cerevisiae’s
transcription factors, the team first collected 1327 publicly available gene expression
microarray data sets for Saccharomyces cerevisiae. Each of these datasets refers to a
specific cellular condition. Next, for each of these conditions, the genes were ordered
based on their expression fold change levels. At the top were the genes that were highly
induced, and at the bottom the ones that were repressed. Parallel to the previous
step, ranks were assigned to the genes according to the PBM P-values of transcription
factors binding to their upstream IGRs. Then using a rank based statistical test, a
comparison was made between the PBM defined ranks of similarly expressed genes
within a sliding foreground window to the ranks of a length-matched background
set of genes outside this window. The result of this statistical test yields a value
which is referred to as the enrichment score and represents the degree to which PBM-
derived target genes of a given TF are significantly enriched within each window of
similarly expressed genes. The statistical significance of the maximum enrichment in
a condition is derived by permutation testing. Using the method described above,
CRACR can list expression conditions in which predicted transcription factor target
genes show statistical significance in expression levels. From such a list of cellular
conditions, one can hypothesize about the functions of the transcription factor.
Difference between CRACR and our approach
• CRACR focuses on similarly expressed genes whereas REPA looks at gene sets
that represent biological pathways. Similarly expressed genes may or may not
belong to the same gene set.
• CRACR attempts to derive information about condition specific gene regulation
and transcription factor binding whereas the goal of this project is to help
provide researchers information about which biological pathways are active in
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the biological condition they are studying along with the transcription factors
that are most likely to regulate these pathways.
• CRACR ranks the genes based on their expression levels and then for each
transcription factor, it compares the p-values (derived from in-vitro PBM ex-
periments) of similarly expressed genes with the p-values of the other genes in
the list. PBM data does not account for the cell’s chromatin state. On the other
hand our approach is dependent on in-vivo ChIP-X data which takes into ac-
count the cell’s chromatin state and hence the results obtained can be expected
to have a higher biological significance although chromatin state depends on
cell’s state and cell line.
• CRACR used data from studies on Saccharomyces cerevisiae (yeast) whereas
this project focuses on human data from the ENCODE project.
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Results and Comparison
The goal of this chapter is to assess the accuracy and strength of REPA. For the first
module, i.e. regulation pathway analysis, we identified TF - gene set associations
with a strong signal and predicted these as true TF - gene set associations. Then we
analyzed the accuracy of these predictions. Since we expect many of the predictions
to be novel, we might not find any evidence in the existing literature confirming
them even when the predictions are correct. This is probably the most significant
contribution of REPA as it points to new research avenues.
For the second module, i.e. enrichment analysis, we look at the results obtained
after running REPA with sample data from studies involving gene expression analysis
and compare the results with preexisting applications.
Finally we combine the results of the two above mentioned parts and present an
alternative analysis of the data.
4.1 Module 1: Regulation Pathway Analysis
The data obtained from the ENCODE project provided transcription factor binding
sites information for 131 distinct human transcription factors. The MSigDB and
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KEGG pathway libraries provided a total of 10192 gene sets. The results obtained
after running the first module of REPA with this data are discussed in the following
sections.
4.1.1 Inferred associations
REPA calculated a permutation-based p-value for a total of 803711 transcription fac-
tor - gene set associations and predicted that 68008(8.5%) of these pairs are true
associations. To explore the effect of the significance threshold used in the Mann-
Whitney U test in the distribution of permutation-based p-values, we set the signifi-
cance threshold at 0.001, 0.01 and 0.05.
Figure 4.1 shows the distribution of permutation based p-values. The plot has
following features that indicate a successful differentiation between real and non-
existing Transcription factor - gene set associations.
1. A peak on the left side, containing Transcription factor - gene set associations
with strong signal for which the null hypothesis was rejected.
2. A uniform distribution between the interval [0.015,1].
3. A peak at the upper end at 1.
The last two features correspond to transcription factor - gene set bindings for
which the null hypothesis was accepted.
We consider the associations that form the peak on the left side as the predicted
true associations. By performing a visual inspection of figure 4.1 we can see that the
peak ends at about 0.015 (shown by the vertical red line). We set this as the cut-off
for significant associations.
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Figure 4.1: Transcription factor - Gene set association distribution
The number of REPA’s predictions varied from 68008 to 29317 depending upon the
significant threshold used for Mann-Whitney U test. Since the permutation based p-
value distribution remain stable at the different significance thresholds for the Mann-
Whitney U test, we set the significant threshold of Mann-Whitney U test to 0.05.
There are total 68,008 (8.5%) associations that form this peak.
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4.1.2 Number of REPA’s predictions per transcription factor
As discussed earlier, we executed module one with over 10,000 gene sets as input.
Several of these gene sets were created based on the location of their member genes or
were computationally generated as described in section 3.3.1. For performing further
analysis including taking a closer look at specific predictions, we only focus on manu-
ally curated gene sets that represent functions or pathways. These gene sets are more
widely studied and usually include findings from more than a single study. Hence,
from now on, we considered predictions involving a total of 2,677 gene sets from the
following sources.
• Canonical pathways and functions representing biological pathways curated by
domain experts. This includes pathway databases such as KEGG (282 gene
sets), GO (1454 gene sets), REACTOME (674 gene sets) and BIOCARTA (217
gene sets).
• Hallmark gene sets representing specific well-defined biological states or pro-
cesses and display coherent expression (Total 50 gene sets).
Out of the 68,008 predictions, 8,948 (13.2%) pass this criterion. Figure 4.2 shows
the number of REPA’s predictions per transcription factor. There are 88 unique tran-
scription factors that could be found in REPA’s predictions. 74 (84%) are associated
to at least one gene set. 28 (37.8%) are associated to more than 50 gene sets and
three (3.4%), namely GR, POL2 and YY1, are associated with more than 500 gene
sets.
Next we discuss why it makes sense that these three transcription factors are
predicted to regulate a large amount of gene sets.
Glucocorticoid Receptor (GR) It is known that GR regulates diverse cellular
functions (such as mitosis and apoptosis) and essential biological processes (such
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Figure 4.2: Predictions per transcription factor
as growth, development, metabolism, and behaviour), and is expressed in most
cell types (Zhou and Cidlowski 2005; Lu and Cidlowski 2005). To explain how
a single transcription factor can regulate such a variety of processes, it has
been proposed that different GR isoforms allow for regulation of genes in a cell
type specific manner, and that each GR isoform regulates both a common and
a unique group of genes in each cell type (Zhou and Cidlowski 2005; Lu and
Cidlowski 2005).
Polymerase (RNA) II (DNA directed) polypeptide A (POL2) The POL2 gene
encodes for the largest subunit of RNA polymerase II, the polymerase that syn-
thesize mRNA in eukaryotes. POL2 is a general transcription factor that initi-
ates transcription and is responsible for transcriptional regulation (Orphanides,
Lagrange, and Reinberg 1996).
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Yin Yang 1 (YY1) YY1 is an ubiquitously expressed transcription factor that reg-
ulates cell proliferation and differentiation, and is a multifunctional mediator of
different signaling pathways that modulates an impressive and increasing list of
genes (Deng et al. 2010)
Thus, one would expect that these three transcription factors regulate many dif-
ferent gene sets and REPA’s results reflect this.
4.1.3 Number of REPA’s predictions per gene set
We also looked at the number of REPA’s predictions per gene set. There were 1,980
canonical pathways, GO gene sets and hallmark gene sets predicted to be regulated by
at least one transcription factor. Out of these 1,980, 30 (or 1.5%) were associated to
more than 30 transcription factors. Figure 4.3 shows gene sets associated by REPA
with at least 25 transcription factors. Many of the gene sets listed in Figure 4.3
are tightly regulated cellular processes. We examined the literature related to the
regulation of the Reactome pathway and the KEGG pathway associated to the largest
number of transcription factors.
The Reactome pathways metabolism of RNA and cell cycle mitotic were the Re-
actome pathways associated to the largest number of transcription factors. The Re-
actome pathway metabolism of RNA has been deleted from Reactome since version
50 (current version is 52); thus, we investigated the cell cycle mitotic pathway which
contains 325 genes. Cell cycle regulation is critical for growth and development,
and its misregulation plays an important role in diseases such as cancer. There is
a large variety of cell cycle programs within a single species that corresponds to
specific cell types, developmental stages or physiological conditions (Harashima, Diss-
meyer, and Schnittger 2013). In the budding yeast, cell cycle is controlled by a large
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Figure 4.3: Predictions per gene set
and complex interacting network of regulatory proteins, and the general organiza-
tion of this control system is conserved across the Eukaryota (Haase and Wittenberg
2014). REPA associated the following 41 transcription factors with the Reactome
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cell cycle mitotic pathway (literature supporting the involvement of these transcrip-
tion factors during the cell cycle is referred to after the corresponding transcription
factor): AP2ALPHA (Prasov and Glaser 2012), AP2GAMMA, ATF1 (Bandyopad-
hyay et al. 2014), BCLAF1, CBX3, CEBPB, CJUN, CREB1, E2F4, E2F6 (Haase
and Wittenberg 2014), ELF1, ELK1 (Demir and Kurnaz 2013), ETS1 (Oikawa and
Yamada 2003), FOXM1 (Wierstra and Alves 2007), GABP (Imaki et al. 2003),
GR (Zhou and Cidlowski 2005; Lu and Cidlowski 2005), HEY1, INI1 (Versteege
et al. 2002), KAP1 (White et al. 2012), MAX (Amati and Land 1994), MTA3,
MXI1 (Lee and Ziff 1999), MYBL2 (Joaquin and Watson 2003), PAX5, PBX3, PML,
POL2, POU2F2 (Prasov and Glaser 2012), RUNX3, SIN3AK20, SMC3, SP1, STAT3,
STAT5A, TAF1, TBLR1, TCF12, WHIP, YY1, ZNF143, and ZNF263. Thus, we
found literature support for 14 (or 34%) of these transcription factors. The central
components of the cell-cycle control system, cyclin-dependent protein kinases (CDKs),
are missing from this list because they were missing from the linked-transcription fac-
tor binding data used as REPA’s input.
The KEGG ribosome pathway consists of 135 genes including the ribosomal pro-
teins and ribosomal RNAs. The mechanisms regulating ribosome biogenesis are only
partially understood, and they are the focus of current research. Recently, ribosome
biogenesis has been linked to various diseases and aging, and studies have revealed an
elaborate control of ribosome biogenesis that requires coordinate regulation of all three
RNA polymerases and that includes feedback and feed-forward loops (Lempiainen
and Shore 2009; Thomson, Ferreira-Cerca, and Hurt 2013). A large number of tran-
scription factors have been implicated in ribosome biogenesis; for instance, roughly 80
factors have been associated in the maturation of the 60S subunit (Thomson, Ferreira-
Cerca, and Hurt 2013). REPA predicted the following 38 transcription factors to be
associated with the KEGG ribosome pathway (supporting literature is referred to
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after the corresponding transcription factor): ATF1, ATF2, ATF3, BCL3, BCLAF1,
CBX3, CEBPB, CJUN, CREB1 (Nosrati, Kapoor, and Kumar 2014), ELF1 (Algire
et al. 2002), ETS1, GABP (Perry 2005), GR (Shah et al. 2002), HEY1, IRF3, MTA3,
MYBL2, NFATC1, NFIC, NRSF, PML (Vilotti et al. 2012), POL2 (Lempiainen and
Shore 2009), POU2F2, RFX5, RUNX3, SIN3AK20, SIX5, SP1 (Perry 2005), SP4,
STAT5A, TAF1 (Lin et al. 2002), TAF7, TBLR1, TCF12, WHIP, YY1 (Perry 2005),
ZNF143, and ZNF263. Thus, we found literature support for 9 (or 24%) of these
transcription factors.
We found an intriguing gene set (i.e., systemic lupus erythematosus (SLE)) among
the top 10 genes sets shown in Figure 4.3, and thus decided to look at the transcription
factors inferred by REPA to be associated with this disease. SLE is an autoimmune
disease with more than 40 genes and loci identified as associated with this disease.
However, these genes and loci only account for 10 to 20% of disease heritability.
This indicates that there are many factors still to be identified (Frangou, Bertsias,
and Boumpas 2013). REPA inferred 37 transcription factors associated with the
KEGG systemic lupus erythematosus pathway which consists of 138 genes. Out
of those 37 transcription factors predicted to regulate genes in the SLE pathway,
we found literature support for 13 (or 35%). The transcription factors associated
by REPA with SLE are the following (supporting literature is referred to after the
corresponding transcription factor): ATF2, ATF3 (Cai et al. 2014), BCLAF1, CBX3,
CEBPB, CEBPD, ETS1 (Lu et al. 2015), FOS (Frangou, Bertsias, and Boumpas
2013), FOXM1, GR (Chen et al. 2015), HEY1, INI1, JUND (Tenbrock et al. 2007),
MBD4 (Balada et al. 2007), MTA3, MYBL2, NFATC1 (Tenbrock et al. 2007), NFIC,
P300 (Leung et al. 2015), PAX5 (Dozmorov, Wren, and Alarco´n-Riquelme 2014),
PML, POL2, POU2F2, RUNX3 (Jeffries et al. 2011), RXRA, SIN3AK20, SP1 (Hikami
et al. 2011), SP4, STAT5A, TAF1, TAF7, TBP (Chauhan et al. 2004), TCF12, TCF3,
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TEAD4, YY1 (Zhao et al. 2012), and ZBTB33.
4.1.4 Literature based evaluation of REPA’s predictions
Since REPA is the first approach to systematically infer relationships between tran-
scription factors and gene sets, there is no benchmark available that can be used
to do a direct comparison. Therefore, to gain intuition into the quality of REPA’s
predictions and assess the level of precision, we performed a literature analysis on
50 randomly selected predictions. The number of predictions we could examine was
limited by available resources as literature curation is a time consuming effort. For
this analysis, we focused only on predictions that associate transcription factors to
well established manually curated gene sets from sources such as KEGG, Biocarta,
Gene Ontology, MSigDB’s hallmark collection and Reactome. These manually cu-
rated gene sets are well studied unlike several other gene sets which could be created
on the basis of a single study. To avoid over-weighting particular transcription fac-
tors, we only allowed two predictions per transcription factor. Related literature was
searched using PubMed, Disgenet (Bauer-Mehren et al. 2011), and ChEA (Lachmann
et al. 2010). Table 4.1 contains the list of 50 randomly selected REPA’s predictions
that we investigated for literature support. The number of genes in the gene sets
examined varied from 57 to 320, and the percentage of genes in the gene set with a
binding signal value varied from 18% to 94% (see third column of Table 4.1).
We classified the evidence found in the literature into four types:
1. Direct evidence
2. Binding evidence
3. Indirect evidence
4. Refuting evidence
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Transcription
Factor
Gene Set (GS)
# of genes in
GS with a
binding signal
value / # of
genes in GS
p-Value
Type of
evidence
Reference
ATF2 Meiosis 38/116 0.001 NE
ATF2 Ribosome 68/135 0.001 I Johnson et al. 2003
BCLAF1 Alcoholism 52/180 0.001 NE
BCLAF1 Chromosome maintenance 49/122 0.001 I Lee et al. 2012b
CEBPB Spliceosome 69/131 0.001 B Lefterova et al. 2010
CEBPB Viral carcinogenesis 128/206 0.001 D Watanabe-Okochi et al. 2013
CJUN FOXO signalling 36/133 0.001 D Xu et al. 2011
CREB1 E2F targets 105/200 0.001 B Zhang et al. 2005b; Martianov et al. 2010
CREB1 MYC targets v1 (Hallmark) 104/200 0.001 B Zhang et al. 2005b
E2F6 Pathways in cancer 145/327 0.001 D Oberley, Inman, and Farnham 2003
E2F6 Signaling by the B Cell Receptor 59/126 0.001 B Lam et al. 1999
ELF1 Huntington’s disease 100/183 0.001 B Hollenhorst et al. 2007
ELF1 Spliceosome 61/131 0.001 B Hollenhorst et al. 2007
FOXM1 Alcoholism 49/180 0.001 NE
GABP Metabolism of RNA 118/330 0.001 B Hollenhorst et al. 2007; Wallerman et al. 2009
GABP Ribosome 64/135 0.001 D Donadini et al. 2006
GR Acute myeloid leukemia 54/57 0.001 D Haarman et al. 2002
GR Neurotrophin signalling 110/120 0.001 I Adachi et al. 2014
HEY1 HIV infection 101/207 0.001 I Pinzone et al. 2015; Wang et al. 2014b
HEY1 RNA transport 75/164 0.001 NE
JUND Alcoholism 48/180 0.001 I Taqi et al. 2011
KAP1 miRNAs in cancer 69/296 0.012 D Min et al. 2013
MBD4 Amyloids 22/83 0.001 NE
MBD4 Systemic lupus erythematosus 25/138 0.002 D Balada et al. 2007
MTA3 Herpes simplex infection 106/188 0.001 NE
MTA3 Ribosome biogenesis in eukaryotes 40/85 0.004 NE
MYBL2 Alcoholism 52/180 0.001 NE
NFATC1 Systemic lupus erythematosus 45/138 0.001 D Lu et al. 2008
NFIC Viral carcinogenesis 107/206 0.005 I Schuur et al. 1995
PAX5 Epstein Barr virus infection 101/203 0.001 D Tierney et al. 2007
PML HTLV I infection 129/263 0.001 D Ariumi et al. 2003
PML Viral carcinogenesis 103/206 0.001 D Singh et al. 2013
POL2
Bacterial invasion of
epithelial cells
65/76 0.001 D Lutay et al. 2013
POL2
Cytokine Cytokine receptor
interaction
156/271 0.001 NE
POU2F2 mTORC1 signaling 89/200 0.001 NE
POU2F2
Transcriptional misregulation
in cancer
47/179 0.001 NE
RUNX3 Metabolism of RNA 140/330 0.001 NE
RUNX3
Protein processing in
endoplasmic reticulum
86/167 0.001 I Evans et al. 2011
SIN3AK20 Metabolism of mRNA 101/284 0.001 D Dong et al. 2007
SP1 Alcoholism 63/180 0.001 D Harada et al. 1998
SP1 Carbon metabolism 51/105 0.002 D Lin, Lai, and Chau 2011
STAT5A Herpes simplex infection 89/188 0.001 R Kriesel et al. 2004
TAF1 Huntington’s disease 87/183 0.001 I Kaji et al. 2005
TAF1 Ribosome 65/135 0.001 D Lin et al. 2002
TCF3 Meiotic synapsis 26/73 0.004 B Cole et al. 2008
TCF12
Class I MHC mediated antigen
processing & presentation
112/251 0.001 NE
TCF12 E2F targets 110/200 0.001 NE
YY1 Oxidative phosphorylation 61/133 0.001 D Lescuyer, Martinez, and Lunardi 2002
YY1 Spliceosome 62/131 0.001 B Mendenhall et al. 2010
ZNF143 RNA Transport 70/164 0.009 I Yuan et al. 2007
Table 4.1: REPA’s predictions evaluated based on the literature. In type of evidence;
B indicates “binding”, D “direct”, I “indirect”, NE “No Evidence” and R “Refuting
Evidence”
Direct evidence indicates that current literature directly links a transcription fac-
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tors with a given gene set; for example, the association of the transcription factor
YY1 with oxidative phosphorylation is supported by promoter analysis for a complex
I gene (NDUFS8) (Lescuyer, Martinez, and Lunardi 2002).
Binding evidence indicates that targets of a transcription factor identified by a
published Chip-Seq or Chip-ChIP study are over-represented in a given gene set.
This type of evidence was found using ChEA. In the case of binding evidence, current
literature does not directly discuss the link of that transcription factor with the given
gene set.
Indirect evidence indicates that current literature suggests the involvement of a
transcription factor in the regulation of a given gene set; for example, in (Taqi et al.
2011), is suggested that a single nucleotide polymorphism (SNP) in the promoter
region of PDYN, which is associated with alcohol-dependence, may impact PDYN
transcription in the human brain and that this SNP is located within a regulatory
region that may be targeted by the transcription factor JUND.
Finally, refuting evidence indicates that current literature contains experimental
data against the prediction; for example, REPA associated STAT5A with herpes
simplex infection; however, current literature (Kriesel et al. 2004) shows that STAT1,
but not STAT5A, binds to the herpes simplex virus latency-associated transcript
promoter.
Out of the 50 predictions investigated, 17 (34%) were supported by direct evi-
dence and 9 (18%) by binding evidence (see Table 4.1). These 26 (52%) associations
supported by direct or binding evidence were correct or likely to be correct associa-
tions. Out of the 50 associations examined, 23 had indirect evidence or could neither
be confirmed nor refuted by current literature. One (2%) of the 50 associations in-
vestigated was considered to be incorrect or likely to be incorrect based on current
literature. These results suggest that REPA’s precision lies above 52%. This level
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of precision is quite promising as several of REPA’s predictions are expected to be
novel and therefore lack literature support. Moreover, gene function predictions with
similar precision levels have been successfully used in yeast (Peng et al. 2003) and
mouse (Pen˜a-Castillo et al. 2008). Based on this, we expect REPA’s predictions to
be an useful resource to guide further biological research.
4.1.5 Estimation of REPA’s recall
The Collection 3: Transcription Factor Targets (C3-TFT) of MSigDB consists of 615
gene sets that contain genes that share a transcription factor binding site defined in the
TRANSFAC (version 7.4, http://www.gene-regulation.com/) database. Each of
these gene sets is annotated by a TRANSFAC record. Additionally, the transcription
factor known to bind the given motif is provided for 500 of these 615 gene sets. In
total, 282 transcription factors are matched to a given DNA-binding motif in the
C3-TFT collection. Out of these 282 transcription factors, 33 are also present in
the linked-TFBD used as REPA’s input, and REPA generated a prediction for 26 of
them (see Figure 4.4). The 7 transcription factors for which REPA did not make a
prediction had binding signal values for very few genes (four of them had binding
signal values for less than 505 genes). To estimate REPA’s recall, we counted the
number of transcription factors associated by REPA with the corresponding C3-TFT
gene set; for instance, since REPA associated SP1 to the V$SP1 01 gene set (which
consists of genes whose promoter regions contain the motif GGGGCGGGGT which
matches annotation for SP1) we counted SP1 as successfully retrieved by REPA.
REPA associated 14 TFs to their corresponding C3-TFT gene set. Based on this,
REPA’s recall is at 53.8% (14/26).
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Figure 4.4: Venn diagram indicating the number of TFs in common between MSigDB
C3-TFT collection, ENCODE’s TFBD and REPA’s predictions.
4.2 Module 2: Enrichment analysis
Over the past decade several methods and software tools were developed to address
the task of enrichment analysis. Many approaches adapted functional class scoring
(FCS) as their preferred technique. As the methods grew in sophistication and became
more matured the accuracy of the results increased (Khatri, Sirota, and Butte 2012;
Khatri and Dra˘ghici 2005).
To test the performance and accuracy of the enrichment analysis using FCS module
of REPA (Regulation Expression Pathway Analysis) we compare our results against
those of Generally Applicable Gene-set Enrichment (GAGE). GAGE is arguably the
most widely used gene set enrichment analysis system. GAGE was published in
the year 2009 (Luo et al. 2009). Before GAGE, tools such as Gene Set Enrichment
Analysis or GSEA (Subramanian et al. 2005) and Parametric Analysis of Gene set
Enrichment or PAGE (Kim and Volsky 2005) were still widely used tools but those
methods had limited usage because they couldn’t handle datasets of different sample
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sizes or experimental designs. GAGE overcame those limitations and when compared
with GSEA and PAGE showed significantly improved results as discussed in (Luo
et al. 2009). The datasets that were used for the comparison between GAGE, GSEA
and PAGE in (Luo et al. 2009) were of varying sample sizes, experimental designs
and microarray profiling techniques. We compare REPA with GAGE using the same
datasets along with one more dataset that was derived from a study done to under-
stand infection of influenza A viruses.
The purpose of this comparison is to confirm that REPA’s results are mostly in
agreement with GAGE’s results. Module 2 was added to REPA for the convenience
of running the complete analysis within the same software. However, results from
REPA’s module 1 (regulatory enrichment) can be combined with results from other
tools for gene set analysis of expression data such as GAGE. REPA’s module 1 is the
novel contribution of this thesis.
4.2.1 Description of the datasets
To perform the comparisons we used the datasets provided by the R package “gage-
Data” (Luo 2013). Gagedata is a supporting data package for the software package,
GAGE (Luo et al. 2009). It contains microarray datasets that GAGE uses in its pa-
per to compare itself against GSEA and PAGE. Therefore the data supplied here is
also useful for our purposes since we can use it to run REPA and compare it against
GAGE.
The R package “gageData” contains the microarray datasets from the following
two experiments.
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Case 1: BMP6 treated vs untreated hMSC
In this study, microarrays were used to profile the global gene expression in human
mesenchymal stem cells (hMSC). These hMSCs were treated with an endogenous
regulator Bone morphogenetic protein 6 or BMP6. The dataset contains a total of 4
gene chip measurements from duplicate experiments each with paired measurements
of human MSC with or without 8 hours of BMP6 treatment (Luo et al. 2009). This is a
typical small dataset with as few as two samples per condition. BMP6 treated samples
and controls are one-on-one matched. This dataset is also registered as GSE13604 in
Gene Expression Omnibus or GEO (Edgar, Domrachev, and Lash 2002).
Case 2: Dataset derived from breast cancer study on 12 patients
This study covers 12 breast cancer patients each with histologically normal (HN),
atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) RMA sam-
ples (Emery et al. 2009). Due to space constraints, the dataset was split into two
halves. The gage package only includes the first half dataset for 6 patients as the
example dataset of this study as gse16873. Most of the comparison analyses that was
done by GAGE were done on these samples. For our comparison purposes we use the
gse16873. This dataset is also registered as GSE16873 in GEO.
Case 3: Infection of influenza A viruses
The goal of this study was to investigate the early host responses of influenza A
viruses in human lung epithelial cells (Gerlach et al. 2013a). Gene expression pro-
filing was performed on host transcriptional responses of well-differentiated, primary
human bronchial epithelial cells during infection of influenza A viruses. We used gene
expression data of uninfected cells and cells infected with H1N1pdm isolates from a
nonfatal case (A/KY/136/09). The data set contains 3 biological replicates for each
70
4.2. MODULE 2: ENRICHMENT ANALYSIS
group. This dataset is also registered as GSE48466 in GEO.
4.2.2 Running GAGE with the datasets
To run GAGE with the first dataset we took the following steps:
1. Load the gage and gageData libraries.
library(gageData)
library(gage)
2. Load the gene sets.
c2.gs=readList("msig5_kegg.txt")
3. Run GAGE with the following arguments.
bmp6.c2.p <- gage(bmp6, gsets = c2.gs, ref =c(1,3),
samp = c(2,4), same.dir = FALSE, compare = "as.group")
Description of the parameters:
• bmp6 contains the gene expression data.
• gsets is a named list. Each element contains a gene set.
• ref = c(1,3) is a numeric vector and indicates that in this data, columns 1
and 3 store the expression levels of the controls.
• samp = c(2,4) indicates that columns 2 and 4 store the expression levels
of the treated samples.
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• same.dir is a boolean. It indicates whether the input gage result test for
changes in a gene set toward a single direction (all genes up or down reg-
ulated, same.dir = TRUE) or changes towards both directions simulta-
neously (same.dir = FALSE). Since in REPA we consider absolute scores
(fold change, log ratio etc.) we set same.dir as FALSE.
• compare = “as.group”. This argument indicates which comparison scheme
to be used. “as.group” indicates that group-on-group comparison between
the controls and treated samples.
4. Finally we select only the cases that gave complete results and are significant
with their adjusted p-values less than 0.01.
results <- bmp6.c2.p$greater[complete.cases(bmp6.c2.p$greater),]
gage.bmp6.sigResults <- results[results[,"q.val"] < 0.01,]
The same procedure was followed for the datasets from case 2.
For case 3, we executed gage with the following parameters:
gage_results_influenza <- gage(gse48466_perGene,
gsets = msigv5_kegg.gs, ref = 10:12, samp =4:6,
same.dir = TRUE, compare = "unpaired")
4.2.3 Running REPA with the datasets
In this section we go through the steps that were taken to run our system with
the datasets provided in the the R package “gageData” (Luo 2013) to perform the
comparison between the two systems.
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Preprocessing with Limma
Limma or Linear Models for Microarray Data is a R package for differential expression
analysis of data arising from microarray experiments (Smyth 2005). We use Limma
with the raw data from the experiments to fit a linear model to the expression data
for each gene.
Inputs to Limma:
1. Design matrix The design matrix for the smaller dataset BMP6 is stored in
a text file called “13604DesignMatrix.txt”. It stores the information shown in
the following table.
Control BMP6 Treated
8hCont1 1 0
8hTrt 8hCult1 0 1
8hCont2 1 0
8hTrt 8hCult2 0 1
Table 4.2: 13604 Design Matrix
The design matrix for the larger dataset follows the same pattern.
2. Microarray data
The second input to Limma is the raw expression level data from the microarray
experiments. Table 4.3 shows the first few rows of the bmp6 dataset.
8hCont1 8hTrt 8hCult1 8hCont2 8hTrt 8hCult2
10000 6.666482 6.727039 7.859644 7.888743
10001 9.874859 9.873068 9.838792 9.757909
10002 5.524512 5.651697 5.299609 5.146715
10003 4.604491 4.661876 4.790255 4.705559
10004 7.904135 7.883218 8.00505 7.962769
...
...
...
...
...
Table 4.3: bmp6 expression data sample
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The expression data table for the larger breast cancer patient dataset also follows
the same pattern.
Steps in running Limma
1. Load the library Limma using the following command.
library(limma)
2. Next load the experiment design matrix.
designMatrix <- read.table("13604DesignMatrix.txt")
3. Fit linear model for each gene from the given series of arrays. The variable
bmp6 holds the data shown in Table 4.3
fit <- lmFit(bmp6, designMatrix)
4. The next step is the contrast step, which uses the contrasts.fit() function. This
allows the fitted coefficients to be compared in as many ways as there are ques-
tions to be answered, regardless of how many or how few these might be.
contrastFit <- makeContrasts(BMP6_Treated-Control, levels=fit)
5. In this step we calculate the empirical Bayes statistics. The eBayes() function
is used to rank genes in order of evidence for differential expression.
eBayesTable <- eBayes(contrastFit)
6. Finally we extract a table of the top-ranked genes from the linear model. bmp6
contains the data from the gagedata library and is shown in the Table 4.3.
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results <- topTable(eBayesTable, adjust = ‘‘fdr’’,
coef = 1, number = nrow(bmp6))
The “results” variable contains the output from Limma. Table 4.4 shows few lines
from the Limma results.
Gene LogFC Avg Expr t P.Val Adj P.Val B
5228 4.066771195 8.984909943 30.01850012 1.75E-06 0.030867069 2.719129297
8200 -2.937752131 9.096127188 -22.30635557 6.85E-06 0.060528957 2.461454621
3400 3.107500295 8.990624466 18.99550122 1.43E-05 0.066519298 2.261904761
133 -3.11990311 9.026165624 -17.69540658 1.98E-05 0.066519298 2.15765175
3399 3.819738229 11.38550593 17.22309034 2.24E-05 0.066519298 2.115050187
Table 4.4: Results after running Limma with bmp6 data
We input the Limma results along with the file containing all the gene sets to
REPA. Few rows of REPA’s output are shown in the following table.
Test Name Gene Set Name Total Genes Values Found <0.001 <0.01 <0.05 >0.05 Average pValue
Two-sample student’s pooled t-test KEGG GLYCOLYSIS GLUCONEOGENESIS 62 60 0 1 12 987 0.461956
Two-sample student’s unpooled t-test KEGG GLYCOLYSIS GLUCONEOGENESIS 62 60 0 1 12 987 0.461977
Mann-Whitney U-test KEGG GLYCOLYSIS GLUCONEOGENESIS 62 60 0 1 3 996 0.521978
Two-sample student’s pooled t-test KEGG CITRATE CYCLE TCA CYCLE 32 30 0 0 0 1000 0.695003
Two-sample student’s unpooled t-test KEGG CITRATE CYCLE TCA CYCLE 32 30 0 0 0 1000 0.694662
Mann-Whitney U-test KEGG CITRATE CYCLE TCA CYCLE 32 30 0 0 0 1000 0.717507
Two-sample student’s pooled t-test KEGG PENTOSE PHOSPHATE PATHWAY 27 26 0 0 3 997 0.414412
Two-sample student’s unpooled t-test KEGG PENTOSE PHOSPHATE PATHWAY 27 26 0 0 2 998 0.414801
Mann-Whitney U-test KEGG PENTOSE PHOSPHATE PATHWAY 27 26 0 0 9 991 0.511711
Table 4.5: Enrichment analysis module results
4.2.4 Comparison between results from GAGE and REPA
In this section we compare the results that were obtained from running GAGE and
REPA with the same gene expression level data and the same gene sets.
Case 1: BMP6 treated vs untreated hMSC
The results obtained after running GAGE and REPA were stored in two lists. Both
the systems were run with the same gene sets and datasets as inputs.
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• The list from GAGE contained 133 gene sets that had an adjusted P.value of
less than 0.01.
• The list from REPA contains 142 gene sets that had a P.value of less than 0.01.
We expected to see some significant overlap of the two as both the systems were
trying to solve the same problem. To analyze the results we look at the results in the
following three ways.
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Figure 4.5: REPA vs GAGE plot for BMP6 dataset
The Spearman’s correlation coefficient between the significant results obtained
from the two systems is 0.491. Correlation coefficient for all the gene sets together is
0.542. In Figure 4.5 each gene set is represented by a circle. On the X-axis we have
the log of REPA p-values and on Y-axis we have the log of GAGE p-values. This
indicates that there is an agreement in how both systems rank the gene sets.
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Figure 4.6: BMP6 dataset Venn diagram
Out of all the total 146 gene sets that were predicted to be significant by both
systems combined, 22.2% were unique to REPA, 16.9% were unique to GAGE and
60.8% were common to both. The Venn diagram of this comparison is shown in
figure 4.6.
Case 2: Dataset derived from breast cancer study on 12 patients
Similar to case 1, we get two lists of gene sets, one each from running GAGE and
REPA. For comparing the results we again look at the correlation coefficients and
the plots. GAGE predicted 463 significant gene sets where as REPA predicted 543
significant gene sets.
The Spearman’s correlation coefficient for the two lists is 0.316 for significant gene
sets and 0.547 for all gene sets combined. Figure 4.7 shows the plot between the two
results.
In this case there were total 658 gene sets that were predicted to be significant by
both systems combined. 17.5% were unique to GAGE whereas 29.6% were unique to
REPA. 52.9% were common to both. The Venn diagram of this comparison is shown
in figure 4.8.
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Figure 4.7: REPA vs GAGE plot for breast cancer dataset
Figure 4.8: Breast cancer dataset Venn diagram
Case 3: Infection of Influenza A viruses
Here, we looked at gene expression profiling data obtained from a study performed
to investigate the early host responses of seasonal and pandemic influenza A viruses
in primary well-differentiated human lung epithelial cells (Gerlach et al. 2013b). We
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used gene expression data of uninfected cells and cells infected with H1N1pdm isolates
from a nonfatal case (A/KY/136/09). We performed enrichment analysis using both
GAGE and REPA on this dataset. Then we compared the list of significant gene sets
produced by both the systems and made the following conclusions:
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Figure 4.9: REPA vs GAGE plot for Infection of Influenza A viruses
Figure 4.10: Infection of Influenza A viruses dataset Venn diagram
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4.3. MODULE 3: COMBINING THE RESULTS FROM THE FIRST TWO
MODULES AND DERIVING CONCLUSIONS
1. Out of the provided 10192 gene sets, REPA predicted 124 (1.22%) gene sets as
significant where GAGE produced a much larger list of 833 (8.17%) significant
gene sets.
2. The spearman’s correlation coefficient (0.6726835 overall; 0.6480139 for signifi-
cant gene sets) and the plot in figure 4.9 shows a higher degree of agreement in
the rankings of the two systems when compared to the previous two cases.
3. Looking at the venn diagrams in figure 4.10, we can see that 119 out of 124 or
95.97% of the gene sets predicted by REPA are also present in the GAGE’s list
of significant gene sets.
In a specific case like this where there is a more comprehensive list generated by
GAGE, we can substitute the results obtained by REPA for module 2 with the results
obtained by GAGE or any other competing software and use them to process with
the results obtained in REPA’s module 1.
4.3 Module 3: Combining the results from the first
two modules and deriving conclusions
The next and final step was to combine the results obtained from the first two modules
and make final conclusions on the data. We looked at each of the three cases described
in the previous section. Although we used all the available 10,192 gene sets for
performing the enrichment analysis in module 2, in this section we only focus on the
canonical pathways and manually curated gene sets. Therefore gene sets from the
following sources:
• KEGG (283 gene sets)
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MODULES AND DERIVING CONCLUSIONS
• Reactome (674 gene sets)
• Biocarta (217 gene sets)
• Gene Ontology (1,454 gene sets)
• MSigDB’s Hallmark gene sets (50)
Total 2,678 gene sets.
4.3.1 Case 1: BMP6 treated vs untreated hMSC
The final results were obtained by combining the outputs of the first two modules.
The list of the statistically significant gene sets (p-value < 0.01 for MWU test with
significant threshold = 0.05) and their likely regulators are given below in table 4.6.
Differentially expressed gene sets REPA’s predicted putative regulators
(H) Genes regulated by NF-kB in response to TNF
POL2, CEBPB, PAX5, GR, TCF12, YY1, TAF1, HEY1, AP2GAMMA, CEBPD,
ATF2, CREB1, SP1, JUND, NFIC, SIN3AK20, E2F6, ELF1, PML, BCLAF1,
P300, CJUN, MTA3, RUNX3, STAT5A, TCF3, BCL3, POU2F2, NFATC1, BAF155
(H) Genes down-regulated in response to
ultraviolet (UV) radiation
POL2, GR, YY1, TAF1, HEY1, CREB1, SP1, E2F6
(H) Genes up-regulated in response to
Interferon Gamma
POL2, CEBPB, PAX5, GR, YY1, HEY1, IKZF1, EBF, E2F6, ELF1, PML,
CJUN, MTA3, RUNX3, STAT5A, SMC3, POU2F2
(H) Inflammatory response POL2, CEBPB, GR, E2F6, MTA3, POU2F2
(H) Genes defining early response to estrogen POL2, GR, E2F6
(K) TGF-beta signaling pathway POL2, GR, YY1, TAF1, E2F6
(H) APOPTOSIS POL2, CEBPB, GR, TCF12, YY1, TAF1, SIN3AK20, E2F6, PML, MTA3, POU2F2
(K) HTLV-I infection
POL2, CEBPB, GR, TCF12, YY1, TAF1, HEY1, CREB1, SP1, SIN3AK20,
EBF, E2F6, ELF1, PML, BCLAF1, ZNF143, CJUN, MTA3, RUNX3, STAT5A,
POU2F2, NFATC1, CBX3, KAP1
(K) TNF signaling pathway
POL2, CEBPB, PAX5, GR, TCF12, YY1, E2F6, ELF1,
PML, BCLAF1, MTA3, RUNX3, POU2F2
(K) Pathways in cancer
POL2, CEBPB, PAX5, GR, TCF12, YY1, TAF1, HEY1, CREB1, SP1,
SIN3AK20, E2F6, ELF1, PML, ZNF143, ATF1, CJUN, MTA3,
RUNX3, STAT5A, POU2F2
(G) Anatomical structures morphogenesis
(H) Genes up-regulated in response to alpha interferon proteins POL2, CEBPB, GR, MTA3
(K) Cytokine-cytokine receptor interaction POL2, CEBPB, GR, E2F6
Table 4.6: Case 1: Final results with the statistically significant gene sets and their
likely regulators
The analysis links the Bmp6 (Bone Morphogenetic Protein 6) to 37 transcription
factors. We could find evidence linking 6 of these 37 transcription factors to the Bmp6
protein. Many of the remaining 31 predictions could be novel and could be discovered
to be true in the future.
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AP2GAMMA, ATF1, ATF2, BAF155, BCL3, BCLAF1, CBX3, CEBPB (Lin
et al. 2013), CEBPD, CJUN, CREB1, E2F6, EBF, ELF1, GR (Kano et al. 2005),
HEY1 (Sivertsen et al. 2007), IKZF1, JUND, KAP1, MTA3, NFATC1, NFIC, P300,
PAX5, PML (Topic´ et al. 2013), POL2, POU2F2, RUNX3, SIN3AK20, SMC3, SP1 (Zhang
et al. 2005a), STAT5A, TAF1, TCF12, TCF3, YY1 (Lee et al. 2004) and ZNF143.
4.3.2 Case 2: Dataset derived from breast cancer study on
12 patients
Out of the total 10,192 gene sets, REPA listed 543 as perturbed. 24 out of these 543
gene sets come from sources such as KEGG, Biocarta, GO, Reactome or MSigDB’s
Hallmark.
The results from module 1 shows that REPA also predicted likely regulators for
22 out of these 24 gene sets. Figure 4.11 provides a full list of these 24 gene sets and
the associated transcription factors.
This list provides clues about likely regulatory mechanisms underlying the ob-
served gene expression changes. REPA’s predictions associated 59 transcription fac-
tors with these 24 gene sets identified as differentially expressed in the breast cancer
expression profiling study. Out of these 59 TFs, 45 (or 76.3%) have previously been
directly linked to breast cancer; namely, AP2ALPHA (McPherson, Woodfield, and
Weigel 2007) AP2GAMMA (McPherson, Woodfield, and Weigel 2007) ATF1 (Jones
et al. 2012) ATF2 (Lau and Ronai 2012) ATF3 (Yin et al. 2010) BAF155 (Wang
et al. 2014a) BCL3 (Choi et al. 2010) BCLAF1 (Savage et al. 2014) BHLHE40 (Wu
et al. 2014; Cadenas et al. 2014) BRCA1 (Wang and Di 2014) CBX3 (Choi, Park,
and Lee 2012) CEBPB (Abreu and Sealy 2010) CJUN (Xu et al. 2013) COREST (Vi-
cent et al. 2013) CREB1 (Phuong et al. 2014) E2F6 (Oberley, Inman, and Farnham
2003) EBF (Geng et al. 2007) ELF1 (Gerloff et al. 2011) ELK1 (Laliotis et al. 2013)
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Differentially+expressed+gene+sets REPA's+predicted+putative+regulators
(R)$SRP'dependent$cotranslational$protein$
targeting$to$membrane
POL2,$CEBPB,$GR,$ZNF263,$TCF12,$YY1,$TAF1,$HEY1,$TAF7,$MYBL2,$GABP,$ATF2,$CREB1,$SP1,$SIX5,$SIN3AK20,$
ELF1,$ETS1,$PML,$BCLAF1,$SP4,$TBLR1,$CJUN,$MTA3,$STAT5A,$WHIP,$NRSF,$BCL3,$POU2F2,$NFATC1,$CBX3
(R)$Antigen$processing'Cross$presentation POL2,$GR,$YY1,$TAF1,$CREB1,$SIN3AK20,$ELF1,$PML,$CJUN,$MTA3,$STAT5A
(R)$ER'Phagosome$pathway POL2,$GR,$YY1,$TAF1,$SIN3AK20,$ELF1,$PML,$CJUN,$MTA3,$STAT5A
(R)$Adaptive$Immune$System
(R)$Translation
POL2,$CEBPB,$GR,$ZNF263,$TCF12,$YY1,$TAF1,$HEY1,$TAF7,$MYBL2,$GABP,$ATF2,$CREB1,$SP1,$SIX5,$SIN3AK20,$
E2F6,$ELF1,$ETS1,$PML,$BCLAF1,$ZNF143,$SP4,$CJUN,$MTA3,$RUNX3,$STAT5A,$WHIP,$NRSF,$BCL3,$POU2F2,$
NFATC1,$CBX3
(R)$Class$I$MHC$mediated$antigen$
processing$&$presentation
POL2,$CEBPB,$PAX5,$GR,$TCF12,$YY1,$TAF1,$HEY1,$AP2GAMMA,$GABP,$CREB1,$SP1,$SIN3AK20,$E2F6,$ELF1,$ETS1,$
PML,$BCLAF1,$ZNF143,$CJUN,$MTA3,$RUNX3,$STAT5A,$POU2F2,$CBX3,$BAF155
(R)$Metabolism$of$proteins
(R)$Metabolism$of$mRNA
POL2,$CEBPB,$PAX5,$GR,$ZNF263,$TCF12,$YY1,$TAF1,$HEY1,$TAF7,$MYBL2,$GABP,$ATF2,$CREB1,$SP1,$NFIC,$SIX5,$
SIN3AK20,$USF2,$E2F6,$ELF1,$ETS1,$PML,$SIN3A,$BCLAF1,$FOXM1,$ZNF143,$SP4,$ATF1,$CJUN,$ELK1,$MTA3,$
RUNX3,$STAT5A,$WHIP,$NRSF,$BCL3,$POU2F2,$NFATC1,$CBX3,$KAP1
(K)$Protein$processing$in$endoplasmic$
reticulum
POL2,$CEBPB,$PAX5,$GR,$ZNF263,$TCF12,$YY1,$TAF1,$HEY1,$CREB1,$SP1,$SIN3AK20,$E2F6,$ELF1,$ETS1,$PML,$
BCLAF1,$ZNF143,$ATF1,$CJUN,$MTA3,$RUNX3,$STAT5A,$SMC3,$POU2F2,$KAP1,$BRCA1
(H)$Genes$defining$early$response$to$
estrogen
POL2,$GR,$E2F6
(H)$Genes$defining$late$response$to$
estrogen
POL2,$CEBPB,$GR,$E2F6
(H)$Genes$defining$epithelial'
mesenchymal$transition,$as$in$wound$
healing,$fibrosis$and$metastasis
POL2,$GR,$E2F6
(H)$Genes$up'regulated$through$
activation$of$mTORC1$complex
POL2,$CEBPB,$PAX5,$GR,$TCF12,$YY1,$TAF1,$HEY1,$MYBL2,$CREB1,$SP1,$SIN3AK20,$E2F6,$ELF1,$PML,$BCLAF1,$
ZNF143,$SP4,$ATF1,$CJUN,$MTA3,$RUNX3,$STAT5A,$POU2F2,$CBX3,$KAP1
(H)$Interferon$gamma$response POL2,$CEBPB,$PAX5,$GR,$YY1,$HEY1,$IKZF1,$EBF,$E2F6,$ELF1,$PML,$CJUN,$MTA3,$RUNX3,$STAT5A,$SMC3,$POU2F2
(H)$Hypoxia
POL2,$CEBPB,$PAX5,$GR,$TCF12,$YY1,$TAF1,$HEY1,$AP2GAMMA,$AP2ALPHA,$CREB1,$SP1,$MBD4,$FOS,$SIN3AK20,$
BHLHE40,$E2F6,$BCLAF1,$MTA3,$STAT5A
(H)$Genes$up'regulated$in$response$to$
alpha$interferon$proteins
POL2,$CEBPB,$GR,$MTA3
(H)$Genes$mediating$programmed$cell$
death$(apoptosis)$by$activation$of$
caspases.
POL2,$CEBPB,$GR,$TCF12,$YY1,$TAF1,$SIN3AK20,$E2F6,$PML,$MTA3,$POU2F2
(H)$Genes$up'regulated$during$unfolded$
protein$response,$a$cellular$stress$
response$related$to$the$endoplasmic$
reticulum.
POL2,$CEBPB,$GR,$TCF12,$YY1,$TAF1,$HEY1,$ATF2,$CREB1,$SP1,$SIN3AK20,$E2F6,$ELF1,$PML,$BCLAF1,$ZNF143,$
CJUN,$MTA3,$STAT5A,$POU2F2
(H)$Genes$encoding$proteins$involved$in$
glycolysis$and$gluconeogenesis
POL2,$CEBPB,$GR,$YY1,$TAF1,$HEY1,$CREB1,$SP1,$SIN3AK20,$E2F6,$ELF1,$PML,$ATF1,$MTA3
(H)$Genes$regulated$by$NF'kB$in$response$
to$TNF
POL2,$CEBPB,$PAX5,$GR,$TCF12,$YY1,$TAF1,$HEY1,$AP2GAMMA,$CEBPD,$ATF2,$CREB1,$SP1,$JUND,$NFIC,$
SIN3AK20,$E2F6,$ELF1,$PML,$BCLAF1,$P300,$CJUN,$MTA3,$RUNX3,$STAT5A,$TCF3,$BCL3,$POU2F2,$NFATC1,$
BAF155
(H)$A$subgroup$of$genes$regulated$by$
MYC$'$version$1$(v1)
POL2,$CEBPB,$PAX5,$GR,$ZNF263,$TCF12,$YY1,$TAF1,$HEY1,$TAF7,$MYBL2,$AP2GAMMA,$GABP,$AP2ALPHA,$ATF2,$
CREB1,$MAX,$SP1,$MBD4,$NFIC,$SIN3AK20,$E2F6,$ELF1,$ETS1,$PML,$BCLAF1,$FOXM1,$ATF3,$ZNF143,$SP4,$COREST,$
CJUN,$MTA3,$RUNX3,$STAT5A,$NRSF,$SMC3,$BCL3,$POU2F2,$NFATC1,$CBX3,$KAP1
(G)$Proteinaceous$extracellular$matrix POL2,$GR
(G)$Oxidoreductase$activity
POL2,$CEBPB,$PAX5,$GR,$TCF12,$YY1,$TAF1,$HEY1,$CREB1,$SP1,$SIN3AK20,$E2F6,$ELF1,$PML,$ZNF143,$ATF1,$CJUN,$
MTA3,$WHIP,$CBX3
(G)$Endoplasmic$reticulum
POL2,$CEBPB,$PAX5,$GR,$ZNF263,$TCF12,$YY1,$TAF1,$HEY1,$AP2GAMMA,$CREB1,$SP1,$SIN3AK20,$E2F6,$ELF1,$
PML,$ZNF143,$ATF1,$CJUN,$MTA3,$RUNX3,$STAT5A,$POU2F2,$CBX3
Figure 4.11: Breast cancer case study results
ETS1 (Furlan et al. 2014) FOXM1 (Koo, Muir, and Lam 2012) GABP (Thomp-
son, MacDonald, and Mueller 2011) GR (Vilasco et al. 2011) HEY1 (Bolo´s et al.
2013) IKZF1 (Yang, Luo, and Wei 2010) KAP1 (Addison et al. 2015) MAX (Il-
iopoulos, Rotem, and Struhl 2011) MBD4 (Cunha et al. 2014) MTA3 (Fujita et
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al. 2003) MYBL2 (Shi et al. 2012) NFATC1 (Yiu et al. 2011) NFIC (Eeckhoute
et al. 2006) NRSF (Bronson et al. 2010) PAX5 (Moelans, Verschuur-Maes, and Di-
est 2011) PML (Carracedo et al. 2012) POL2 (Han et al. 2014) RUNX3 (Bai et al.
2013) SMC3 (Wernicke et al. 2011) SP1 (Kong et al. 2014) SP4 (Wu et al. 2009)
STAT5A (Zeng et al. 2014) TAF1 (McDonnell et al. 1995) TBLR1 (Li et al. 2014)
TCF12 (Lee et al. 2012a) and YY1 (Lieberthal et al. 2009; Wan et al. 2012).
These results indicate that REPA’s precision may be higher than the one suggested
by our literature-based evaluation done in section 4.1.4. Moreover, REPA’s predictions
suggested 14 additional transcription factors that may play a role in breast cancer.
These are CEBPD, FOS, JUND, P300, POU2F2, SIN3A, SIN3AK20, SIX5, TAF7,
TCF3, USF2, WHIP, ZNF143 and ZNF263. Some of these 14 additional regulators
have already been implicated in other types of cancer.
4.3.3 Case 3: Infection of influenza A viruses
In the previous section, we discussed that when we used REPA’s enrichment analysis
module to analyze this data set, we got a list of 124 perturbed gene sets. GAGE, on
the other hand, predicted 833 gene sets to be active. Since GAGE’s list was more
comprehensive and includes 119 out of 124 of REPA’s predictions, we substituted the
results of module 2 with GAGE’s results.
To reduce the amount of redundancy in GAGE results, we compared every pair
of differentially expressed gene sets. We obtained the number of genes in common
between each pair and removed those gene sets with a significant overlap with another
gene set (p-value < 0.0001 using the hypergeometric distribution) and at least 50%
of their genes lying on the intersection between both gene sets. This filtering reduced
the number of gene sets by 70%; however, the number of associated TFs decreased by
only 7%. This indicates that REPA’s predictions are replicated in different annotation
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scheme.
Figure 4.12: Infection of influenza A viruses case study results
In the original study, pathway analyses were performed using Ingenuity Pathway
Analysis (IPA, Ingenuity Systems) software. As in the original study, we identified
gene sets related to cytokine signalling, interferon signalling, apoptosis, complement
system, and antigen presentation. In addition, we identified several influenza-related
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gene sets (see figure 4.12).
Upon identification of the differentially expressed gene sets, we used REPA’s pre-
dictions to list putative regulators of those differentially expressed gene sets (see fig-
ure 4.12). REPA’s predictions associated 58 TFs with the gene sets identified as dif-
ferentially expressed in the influenza infection transcriptional profiling study. These
58 TFs are the following (supporting literature is referred to after the corresponding
TF): AP2ALPHA, AP2GAMMA, ATF1, ATF2 (Hrincius et al. 2010), ATF3 (Whit-
more et al. 2007), BAF155, BCL3, BCLAF1, BRCA1, CBX3, CEBPB (Zhu et al.
2010), CEBPD, CJUN (Cannon et al. 2014), COREST, CREB1 (Liu et al. 2012),
E2F4 (Zhu et al. 2010), E2F6 (Zhu et al. 2010), EBF, ELF1, ELK1 (Harii et al. 2005),
ETS1, FOXM1, GABP, GR (Ge et al. 2011), HEY1, IKZF1, INI1, JUND, KAP1,
MAX, MBD4, MTA3, MYBL2, NFATC1 (Zhang et al. 2009), NFIC, NRSF, P300,
PAX5 (Savitsky and Calame 2006), PML (Li et al. 2009), POL2, POU2F2 (Bussfeld
et al. 1997), PU1, RFX5, RUNX3, SIN3AK20, SMC3, SP1 (Barbier et al. 2012),
SP4, STAT5A, TAF1, TAF7, TBLR1, TCF12, TCF3, USF2, YY1, ZNF143, and
ZNF263. We found literature linking with influenza infection 14 (or 24%) of these
TFs. Additionally, ATF3 and SP1 were found to be expressed in cells infected with
pandemic influenza A virus (H1N1pdm) but not in cells infected with seasonal in-
fluenza virus (Gerlach et al. 2013a).
4.4 Summary
In this chapter, we present the results of evaluating REPA. Our results suggested
that between 24% and 76% of the regulatory associations predicted by REPA are
likely correct, and that REPA’s recall is around 54%. In addition, REPA’s module
2 results are mostly in agreement with the gene sets obtained by GAGE, a widely
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used tool for gene set analysis of expression data. This suggests that REPA’s novel
predicted regulatory associations may indeed be useful to guide further biological
investigations.
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Chapter 5
Conclusion
To measure the activity levels of various genes, biologists often use gene expression
profiling experiments. After obtaining the activity levels of all the genes and analyz-
ing the data from such experiments, researchers then resort to enrichment analysis
techniques. Enrichment analysis is usually the next step after performing a gene ex-
pression profiling experiment because it helps researchers gain a better understanding
of the cellular activities and processes relevant to the study performed. Transcription
factors are regulator proteins that control the level of activity of various genes. A
transcription factor usually regulates a gene by binding to its promoter region. Tran-
scription factor binding (TFB) data for the entire human genome was made publicly
available under the ENCODE project. Even though there is an important relation-
ship between transcription factors and biological pathways, so far enrichment analysis
techniques have not looked at those connections.
In this thesis we developed a novel method of analyzing TFB data and com-
bining it with gene set enrichment analysis. An article describing REPA has been
accepted for publication in the IEEE/ACM Transactions on Computational Biology
and Bioinformatics journal. We also built a software application, REPA (Regulation
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Enrichment Pathway Analysis), as an implementation of this approach. We explored
the appropriate statistical testing methods for our purpose and evaluated the results
of this new approach.
The greatest advantage of using REPA is that it allows the user to see a more
complete picture of the cellular activity by providing information about which tran-
scription factors may regulate the genes being affected in an expression profiling study.
Our hope is that by informing researchers about likely regulators, they might be able
to identify future research paths that could have been overlooked.
We can further improve the accuracy and scope of REPA by looking at certain
aspects of the system. By adding TFB data for other species we can use the same
system to analyze other species. We can also use orthology relationships to transfer
information between species. We also want to test the system with biological data
from ongoing wet lab experiments. Finally, having the system as a web service will
make the tool accessible to a larger research community.
We found literature backing several of the predictions relating transcription factors
to gene sets, and we found that there was a significant overlap between the results of
GAGE and the enrichment analysis part of REPA. Even though the results from these
tests appear to be promising, the final test would be in the hands of the researchers in
terms of whether or not they find REPA useful and continue using it as their preferred
enrichment analysis technique.
One of the challenges we faced while doing this project is the lack of transcription
factor binding data for all the known human transcription factors. There are over
1,391 known sequence-specific DNA-binding human transcription factors (Vaquerizas
et al. 2009) however, in this project, we have information of only 120 transcription
factors. The ENCODE project was the first effort to undertake this massive task of
functionally annotating human DNA, but with the advent of new DNA sequencing
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techniques more and more such data can be generated for a much lower cost (Resnick
2011). As these technologies become less expensive and start producing more data,
our approach will have the information it needs to become more accurate. Therefore
it is fair to say that the biggest significance of this project is that it takes enrichment
analysis in a new direction where it will be possible to provide information on not
only which gene sets are interesting, but also how they are regulated.
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Appendix A
R script used for comparing REPA
with GAGE.
A.1 Dataset 1: 8 hours BMP6 treated vs untreated
human mesenchymal stem cells
# 13604 Comparison S c r i p t
# To i n s t a l l the gage package , s t a r t R and enter :
source ( ” http : //bioconductor . org/ b i o c L i t e .R” )
b i o c L i t e ( ” gage ” )
#To i n s t a l l t he a u x i l l a r y data f o r gage package :
b i o c L i t e ( ”gageData” )
# Load L i b r a r i e s
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MESENCHYMAL STEM CELLS
l ibrary ( gageData )
l ibrary ( gage )
# Set working d i r
setwd ( ”GAGE Comparison” )
# Run gage and g e t r e s u l t s o f a n a l y s i s
c2 . gs=readL i s t ( ” c2 c5 c6 hal lmark kegg 12 Apr i l2015 . txt ” )
data (bmp6)
lapply ( c2 . gs [ 1 : 3 ] , head )
head (rownames(bmp6) )
bmp6 . c2 . p <− gage (bmp6 , g s e t s = c2 . gs , r e f =c ( 1 , 3 ) , samp = c
( 2 , 4 ) , same . dir = FALSE, compare = ” as . group” )
r e s u l t s <− bmp6 . c2 . p$ g r e a t e r [ complete . c a s e s (bmp6 . c2 . p$ g r e a t e r
) , ]
gage . bmp6 . s i g R e s u l t s <− r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ]
r e s u l t sA l l S y s t em s <− l i s t ( )
r e s u l t sA l l S y s t em s $gageBMP6 <− row .names( gage . bmp6 . s i g R e s u l t s )
write . table ( f i l e = ” gage13604 r e s u l t s . txt ” , r e s u l t s , sep = ”\
t ” )
system <− read . table ( ”13604 system r e s u l t s . txt ” , sep = ”\ t ” ,
header = FALSE, s t r i ng sAsFac to r s = FALSE)
system$pvalue <− 1 .001 − (system [ , ”V4” ] + system [ , ”V5” ] ) /1000
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row .names(system ) <− system [ , ”V1” ]
system <− system [ row .names( r e s u l t s ) , ]
length ( intersect (system [ system [ , ” pvalue ” ] < 0 . 01 , ”V1” ] , row
.names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) ) )
s i g n i f i c a n t B o t h <− union (system [ system [ , ” pvalue ” ] < 0 . 01 , ”
V1” ] , row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) )
# For a l l gene s e t s
cor (system [ row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) , ”
pvalue ” ] , r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 01 , ”q . va l ” ] ,
method = ”spearman” )
# For s i g n i f i c a n t gene s e t s
cor (system [ s i gn i f i c an t Bo th , ” pvalue ” ] , r e s u l t s [
s i gn i f i c an tB ot h , ”q . va l ” ] , method = ”spearman” )
# Generate REPA vs GAGE p l o t .
pdf ( ” Plot 13604 Comparison . pdf ” )
plot(−log10 (system [ row .names( r e s u l t s ) , ” pvalue ” ] ) , −log10 (
r e s u l t s [ , ”q . va l ” ] ) , main = ”” , ylab = ”−l og10 GAGE
pvalues ” , xlab = ”−l og10 REPA pvalues ” )
l ines ( lowess ( x= −log10 (system [ row .names( r e s u l t s ) , ” pvalue ” ] )
, y = −log10 ( r e s u l t s [ , ”q . va l ” ] ) ) , col = ” red ” , lwd = 2)
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PATIENTS
dev . of f ( )
# Generate venn diagram
l ibrary ( g p l o t s )
pdf ( ”Venn 13604 Comparison . pdf ” )
venn ( l i s t (GAGE= row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 01 ,
] ) , REPA = system [ system [ , ” pvalue ” ] < 0 . 01 , 1 ] ) )
dev . of f ( )
A.2 Dataset 2: Derived from breast cancer study
on 12 patients
# To i n s t a l l the gage package , s t a r t R and enter :
source ( ” http : //bioconductor . org/ b i o c L i t e .R” )
b i o c L i t e ( ” gage ” )
#To i n s t a l l t he a u x i l l a r y data f o r gage package :
b i o c L i t e ( ”gageData” )
# load the gage and gageData l i b r a r i e s :
l ibrary ( gageData )
l ibrary ( gage )
# load the gene s e t s
c2 . gs <− r eadL i s t ( ” gene s e t s . txt ” )
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#item Run GAGE with the f o l l o w i n g arguments .
data ( gse16873 )
lapply ( c2 . gs [ 1 : 3 ] , head )
head (rownames( gse16873 ) )
gse16873 . c2 . p <− gage ( gse16873 , g s e t s = c2 . gs , r e f =c ( 1 , 3 , 5 ) ,
samp = c ( 2 , 4 , 6 ) , same . dir = FALSE, compare = ” as . group” )
r e s u l t s <− gse16873 . c2 . p$ g r e a t e r [ complete . c a s e s ( gse16873 . c2 . p
$ g r e a t e r ) , ]
gage . gse16873 . s i g R e s u l t s <− r e s u l t s [ r e s u l t s [ , ”q . va l ” ] <
0 . 0 1 , ]
write . table ( f i l e = ” gage r e s u l t s 16873 . txt ” , r e s u l t s , sep = ”
\ t ” )
r e s u l t sA l l S y s t em s <− l i s t ( )
r e s u l t sA l l S y s t em s $gageGSE16873 <− row .names( gage . gse16873 .
s i g R e s u l t s )
write . table ( f i l e = ” gage r e s u l t s 16873 . txt ” , r e s u l t s , sep = ”
\ t ” )
system <− read . table ( ”GSE16873 Repa Resu l t s . txt ” , sep = ”\ t ” ,
header = FALSE, s t r i ng sAsFac to r s = FALSE)
system <− system [ , c ( 1 : 5 ) ]
system$pvalue <− 1 .001 − (system [ , ”V4” ] + system [ , ”V5” ] ) /1000
row .names(system ) <− system [ , ”V1” ]
system <− system [ row .names( r e s u l t s ) , ]
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length ( intersect (system [ system [ , ” pvalue ” ] < 0 . 01 , ”V1” ] , row
.names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) ) )
s i g n i f i c a n t B o t h <− union (system [ system [ , ” pvalue ” ] < 0 . 01 , ”
V1” ] , row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) )
# For a l l gene s e t s
cor (system [ row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) , ”
pvalue ” ] , r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 01 , ”q . va l ” ] ,
method = ”spearman” )
# For s i g n i f i c a n t gene s e t s
cor (system [ s i gn i f i c an t Bo th , ” pvalue ” ] , r e s u l t s [
s i gn i f i c an tB ot h , ”q . va l ” ] , method = ”spearman” )
# Generate REPA vs GAGE p l o t .
pdf ( ” Plot 16873 Comparison . pdf ” )
plot(−log10 (system [ row .names( r e s u l t s ) , ” pvalue ” ] ) , −log10 (
r e s u l t s [ , ”q . va l ” ] ) , main = ”” , ylab = ”−l og10 GAGE
pvalues ” , xlab = ”−l og10 REPA pvalues ” )
l ines ( lowess ( x= −log10 (system [ row .names( r e s u l t s ) , ” pvalue ” ] )
, y = −log10 ( r e s u l t s [ , ”q . va l ” ] ) ) , col = ” red ” , lwd = 2)
dev . of f ( )
# Generate venn diagram
l ibrary ( g p l o t s )
pdf ( ”Venn 16873 Comparison . pdf ” )
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venn ( l i s t (GAGE= row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 01 ,
] ) , REPA = system [ system [ , ” pvalue ” ] < 0 . 01 , 1 ] ) )
dev . of f ( )
write . table ( f i l e = ” gage s i g r e s . txt ” , r e s u l t s [ r e s u l t s [ , ”q .
va l ” ] < 0 . 0 1 , ] , sep = ”\ t ” )
write . table ( f i l e = ” repa s i g r e s . txt ” , system [ system [ , ”
pvalue ” ] < 0 . 01 , ”V1” ] , sep = ”\ t ” )
A.3 Dataset 3: Infection of influenza A viruses
# To i n s t a l l the gage package , s t a r t R and enter :
source ( ” http : //bioconductor . org/ b i o c L i t e .R” )
b i o c L i t e ( ” gage ” )
#To i n s t a l l t he a u x i l l a r y data f o r gage package :
b i o c L i t e ( ”gageData” )
# Load L i b r a r i e s
l ibrary ( gageData )
l ibrary ( gage )
# Set working d i r
setwd ( ”GAGE Comparison” )
### Code f o r I n f l u e n z a A
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msigv5 kegg . gs <− r eadL i s t ( ”msig5 kegg . txt ” )
length ( msigv5 kegg . gs )
#Early hos t responses o f s e a s o n a l and pandemic i n f l u e n z a A
v i r u s e s in primary we l l−d i f f e r e n t i a t e d human lung
e p i t h e l i a l c e l l s .
#PMID: 24244384 Gerlach2013
# load s e r i e s and p la t form data from GEO
l ibrary ( Biobase )
l ibrary (GEOquery)
gse48466 raw <− getGEO( ”GSE48466” , GSEMatrix =TRUE)
i f ( length ( gse48466 raw ) > 1) idx <− grep ( ”GPL570” , attr (
gse48466 raw , ”names” ) ) else idx <− 1
gse48466 raw <− gse48466 raw [ [ idx ] ]
# load NCBI p la t form annotat ion
gpl <− annotat ion ( gse48466 raw )
p l a t f <− getGEO( gpl , AnnotGPL=TRUE)
ncb i fd <− data . frame ( attr ( dataTable ( p l a t f ) , ” t ab l e ” ) )
probe ent r e z <− ncb i fd [ , c ( ”ID” , ”Gene . ID” ) ]
probe ent r e z <− probe ent r e z [ probe ent r e z$Gene . ID != ”” , ]
probe ent r e z <− probe ent r e z [ ! g r ep l ( ”///” , probe ent r e z$Gene .
ID , f i x e d = TRUE) , ] # f i l t e r promiscuous probes
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row .names( probe ent r e z ) <− probe ent r e z [ , 1 ]
head ( probe ent r e z )
gse48466 <− exprs ( gse48466 raw )
head ( gse48466 )
length ( intersect (row .names( gse48466 ) , probe ent r e z [ , ”ID” ] ) )
#Get average i n t e n s i t y per gene Entrez ID
gse48466 perGene <− apply ( gse48466 , 2 , function (c , f ) {
tapply (c , f ,mean)
} , probe ent r e z [ row .names( gse48466 ) , 2 ] )
gse48466 perGene <− log2 ( gse48466 perGene )
gage r e s u l t s i n f l u e n z a <− gage ( gse48466 perGene , g s e t s =
msigv5 kegg . gs , r e f = 10 :12 , samp =4:6 , same . dir = TRUE,
compare = ” unpaired ” )
r e s u l t s <− gage r e s u l t s i n f l u e n z a $ g r e a t e r [ complete . c a s e s ( gage
r e s u l t s i n f l u e n z a $ g r e a t e r ) , ]
gage . i n f l u e n z a . s i g R e s u l t s <− r e s u l t s [ r e s u l t s [ , ”q . va l ” ] <
0 . 0 1 , ]
r e s u l t sA l l S y s t em s <− l i s t ( )
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r e s u l t sA l l S y s t em s $ gage in f l u enza <− row .names( gage . i n f l u e n z a .
s i g R e s u l t s )
write . table ( f i l e = ” gage r e s u l t s i n f l u e n z a . txt ” , r e s u l t s , sep
= ”\ t ” )
system <− read . table ( ” repa r e s u l t s i n f l u e n z a . txt ” , sep = ”\ t ”
, header = FALSE, s t r i ng sAsFac to r s = FALSE)
#system <− read . t a b l e (” repa r e s u l t s 13604. t x t ” , sep = ”\ t ” ,
header = FALSE, s t r i n g s A s F a c t o r s = FALSE)
system <− system [ , c ( 1 : 5 ) ]
system$pvalue <− 1 .001 − (system [ , ”V4” ] + system [ , ”V5” ] ) /1000
row .names(system ) <− system [ , ”V1” ]
system <− system [ row .names( r e s u l t s ) , ]
length ( intersect (system [ system [ , ” pvalue ” ] < 0 . 01 , ”V1” ] , row
.names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) ) )
s i g n i f i c a n t B o t h <− union (system [ system [ , ” pvalue ” ] < 0 . 01 , ”
V1” ] , row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) )
# For a l l gene s e t s
cor (system [ row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) , ”
pvalue ” ] , r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 01 , ”q . va l ” ] ,
method = ”spearman” )
# For s i g n i f i c a n t gene s e t s
cor (system [ s i gn i f i c an t Bo th , ” pvalue ” ] , r e s u l t s [
s i gn i f i c an tB ot h , ”q . va l ” ] , method = ”spearman” )
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# Generate REPA vs GAGE p l o t .
pdf ( ” Plot i n f l u e n z a Comparison . pdf ” )
plot(−log10 (system [ row .names( r e s u l t s ) , ” pvalue ” ] ) , −log10 (
r e s u l t s [ , ”q . va l ” ] ) , main = ”” , ylab = ”−l og10 GAGE
pvalues ” , xlab = ”−l og10 REPA pvalues ” )
l ines ( lowess ( x= −log10 (system [ row .names( r e s u l t s ) , ” pvalue ” ] )
, y = −log10 ( r e s u l t s [ , ”q . va l ” ] ) ) , col = ” red ” , lwd = 2)
dev . of f ( )
# Generate venn diagram
l ibrary ( g p l o t s )
pdf ( ”Venn i n f l u e n z a Comparison . pdf ” )
venn ( l i s t (GAGE= row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 01 ,
] ) , REPA = system [ system [ , ” pvalue ” ] < 0 . 01 , 1 ] ) )
dev . of f ( )
# 13606 Comparison S c r i p t
# Load L i b r a r i e s
l ibrary ( gageData )
l ibrary ( gage )
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# Set working d i r
setwd ( ”GAGE Comparison” )
# Run gage and g e t r e s u l t s o f a n a l y s i s
c2 . gs=readL i s t ( ” c2 . a l l . v4 . 0 . en t r e z . gmt” )
data (bmp6)
lapply ( c2 . gs [ 1 : 3 ] , head )
head (rownames(bmp6) )
bmp6 . c2 . p <− gage (bmp6 , g s e t s = c2 . gs , r e f =c ( 1 , 3 ) , samp = c
( 2 , 4 ) , same . dir = FALSE, compare = ” as . group” )
r e s u l t s <− bmp6 . c2 . p$ g r e a t e r [ complete . c a s e s (bmp6 . c2 . p$ g r e a t e r
) , ]
gage . bmp6 . s i g R e s u l t s <− r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ]
r e s u l t sA l l S y s t em s <− l i s t ( )
r e s u l t sA l l S y s t em s $gageBMP6 <− row .names( gage . bmp6 . s i g R e s u l t s )
write . table ( f i l e = ” gage13606 r e s u l t s . txt ” , r e s u l t s , sep = ”\
t ” )
system <− read . table ( ”13606 system r e s u l t s . txt ” , sep = ”\ t ” ,
header = FALSE, s t r i ng sAsFac to r s = FALSE)
system$pvalue <− 1 .001 − (system [ , ”V4” ] + system [ , ”V5” ] ) /1000
row .names(system ) <− system [ , ”V1” ]
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system <− system [ row .names( r e s u l t s ) , ]
length ( intersect (system [ system [ , ” pvalue ” ] < 0 . 01 , ”V1” ] , row
.names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) ) )
s i g n i f i c a n t B o t h <− union (system [ system [ , ” pvalue ” ] < 0 . 01 , ”
V1” ] , row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) )
# For a l l gene s e t s
cor (system [ row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 0 1 , ] ) , ”
pvalue ” ] , r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 01 , ”q . va l ” ] ,
method = ”spearman” )
# For s i g n i f i c a n t gene s e t s
cor (system [ s i gn i f i c an t Bo th , ” pvalue ” ] , r e s u l t s [
s i gn i f i c an tB ot h , ”q . va l ” ] , method = ”spearman” )
# Generate REPA vs GAGE p l o t .
pdf ( ” Plot 13606 Comparison . pdf ” )
plot(−log10 (system [ row .names( r e s u l t s ) , ” pvalue ” ] ) , −log10 (
r e s u l t s [ , ”q . va l ” ] ) , main = ”” , ylab = ”−l og10 GAGE
pvalues ” , xlab = ”−l og10 REPA pvalues ” )
l ines ( lowess ( x= −log10 (system [ row .names( r e s u l t s ) , ” pvalue ” ] )
, y = −log10 ( r e s u l t s [ , ”q . va l ” ] ) ) , col = ” red ” , lwd = 2)
dev . of f ( )
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# Generate venn diagram
l ibrary ( g p l o t s )
pdf ( ”Venn 16873 Comparison . pdf ” )
venn ( l i s t (GAGE= row .names( r e s u l t s [ r e s u l t s [ , ”q . va l ” ] < 0 . 01 ,
] ) , REPA = system [ system [ , ” pvalue ” ] < 0 . 01 , 1 ] ) )
dev . of f ( )
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